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G protein-coupled receptor (GPCR) signaling is the primary method eukaryotes use to respond to 
specific cues in their environment. However, the relationship between stimulus and response for each 
GPCR is difficult to predict due to diversity in natural signal transduction architecture and expression. 
Using genome engineering in yeast, we here constructed an insulated, modular GPCR signal 
transduction system to study how the response to stimuli can be predictably tuned using synthetic 
tools. We delineated the contributions of a minimal set of key components via computational and 
experimental refactoring, identifying simple design principles for rationally tuning the dose-response. 
Using five different GPCRs, we demonstrate how this enables cells and consortia to be engineered 
to respond to desired concentrations of peptides, metabolites, and hormones relevant to human 
health. This work enables rational tuning of cell sensing, while providing a framework to guide 
reprogramming of GPCR-based signaling in other systems. 
INTRODUCTION 
G protein-coupled receptors (GPCRs) are widely represented in most lifeforms and comprise the 
largest family of signaling proteins in humans, with over 800 members detecting structurally diverse 
agonists (Fredriksson, 2003; Pierce et al., 2002). Their abundance and ubiquity to all cell types makes 
them one of the most important signaling pathway classes in healthcare, but also one of the most 
complex (Marinissen and Gutkind, 2001; Santos et al., 2017). Multiple types of G protein-based 
signaling are seen and the downstream signal transduction to activate gene expression is typically 
complex and intertwined with other pathways (Kenakin, 2013; Neves, 2002). The nature of signal 
transduction through the pathway also depends on many different factors, including the stoichiometry 
of the signaling proteins, the presence of inherent feedback mechanisms, and even cellular history 
(Selbie and Hill, 1998). Altogether, this makes it difficult to delineate receptor and signaling properties 
simply from measuring the activation of downstream targets (Prezeau et al., 2010). It also makes it a 
major challenge to predict how changes in the levels of pathway components, for example due to 
different environments or mutations, can affect the performance of a given signaling pathway. 
One of the most studied examples of eukaryotic GPCR signaling is the pheromone response pathway 
of Saccharomyces cerevisiae (Bardwell, 2004), having been the focus of significant efforts from 
systems biology to model its actions via quantification of its behavior (Yu et al., 2008). To understand 
this pathway, researchers have parsed the contributions of numerous studies that have perturbed the 
dose-response and dynamics of the native system by changing growth conditions, by protein 
mutagenesis, via traditional gene overexpression and knockout methods, and more recently using 
optogenetics (Alvaro and Thorner, 2016; Atay and Skotheim, 2017; Harrigan et al., 2018). While these 
efforts have helped to build our best picture of the events required for the transduction of signal from 
agonist to gene activation, inability to control the whole pathway in these experiments has meant that 
a complete system for exploring the dose-response relationship has not yet been achieved (Atay and 
Skotheim, 2017). 
In silico approaches typically model a system by concentrating only on the key components and 
varying important parameters of these such as their expression levels, while removing other non-key 
interactions from consideration (Aldridge et al., 2006; Kholodenko, 2006). With advanced genome 
engineering and synthetic biology tools available, it now becomes possible to take an equivalent 
modelling approach in vivo, removing any non-essential interactions via gene knockout and finely 
tuning the expression of the key components using promoter libraries (Chan et al., 2005; Temme et 
al., 2012). This engineering approach – known as refactoring – makes a system easier to study by 
removing all non-essential natural regulation and feedback, thus enabling the system to be more 
efficiently tuned and directly measured. Effectively this generates cells streamlined for improved 
understanding of pathways and systems, while also making these cells more straightforward to utilize 
in downstream applications. 
Here, we used genome engineering to construct a heavily-modified yeast suitable as an in vivo model 
for tuning GPCR signaling. By removing non-essential components, native transcriptional feedback 
regulation, and all connections to the mating response we built a model strain retaining only the core 
signaling elements. In conjunction with a mathematical model, we used promoter libraries to vary the 
key components in this simplified, refactored pathway and uncovered principles for tuning the 
sensitivity, basal activity, and signal amplitude of the dose-response curve via expression level. This 
new knowledge provides us with a rational approach for tuning signaling characteristics and, as we 
demonstrate, enables us to quickly reprogram yeast to sense and measure a variety of different 




A Highly-Engineered Model Strain for Probing the Signaling Pathway Response 
Glucose sensing and the pheromone response pathway are the two native GPCR signaling pathways 
in S. cerevisiae (Versele et al., 2001), and the latter has long been the go-to choice for coupling 
heterologous GPCRs to yeast gene expression or for building systems for evolving GPCRs to desired 
targets (Dong et al., 2010; Ladds et al., 2005a). Core to this pathway is an extensively-studied 
mitogen-activated protein kinase (MAPK) signaling cascade that functions with its own intrinsic 
feedback to maintain a robust input-output relationship in varying conditions (Chen and Thorner, 
2007). As this MAPK cascade displays a graded, linear response with respect to dose and can be 
considered as a black-box processing unit in transduction through the pathway (Bashor et al., 2008; 
Kofahl and Klipp, 2004; Poritz et al., 2001), we chose to make this natural system the core from which 
we build and tune GPCR signaling pathways. 
Keeping the five genes of the MAPK cascade fixed, we set out to generate a model strain for our work 
by first removing all other GPCR pathway-related genes from S. cerevisiae (Figure 1). This required 
making precise changes at 18 genomic loci in BY4741 yeast, generating our model strain, yWS1922, 
via nine rounds of CRISPR/Cas9-mediated editing (Figure S1A-S1C). Genomic changes were 
validated at each round by PCR and locus sequencing followed by long-read nanopore sequencing 
of the final strain (Figure S1D+S1E). 
During strain construction, we added addressable 24 bp targets in place of the open reading frames 
(ORFs) of all deleted genes. These allow for rapid and markerless (re)insertion of native or 
heterologous ORFs into these locations at high efficiency by CRISPR-aided multiplex integration 
(Figure S1F-S1H). For stable single-copy addition of further genes, three highly-characterized 
landing pads were also introduced that interface with the MoClo Yeast Toolkit (YTK) modular cloning 
system, which enables rapid multigene construction from high-characterized parts (Lee et al., 2015). 
These changes were designed to facilitate rapid exploration of the effects of altering individual 
components of the pheromone response pathway. 
To determine how the model strain performed with all non-essential components removed, the native 
GPCR (STE2), Gɑ (GPA1), Gβ(STE4), Gγ(STE18) and pheromone responsive transcription factor 
(STE12) genes were restored at their natural loci to generate the “Quasi-WT” strain (Figure S1H). 
The ɑ-factor dose-response of this strain was then compared to BY4741 yeast using the pheromone 
response FUS1 promoter driving sfGFP expression (Hagen et al., 1991; Minic et al., 2005). As 
expected, a substantial increase in sensitivity and signal output was observed upon minimizing the 




Figure 1. A Model GPCR Strain for Probing Pathway Performance. 
(A) Pathway variants are generated by assembling the key signaling components into a single multigene cassette, using a 
library of well-characterized promoters to vary the expression, and then chromosomally integrating into the model strain, 
yWS1922, to reconstitute a minimized GPCR signaling pathway. 
(B) 11 of the 15 genes deleted from the yeast mating and glucose-sensing pathways in the model strain, leaving only the 
core signaling elements of the MAPK cascade intact. 
(C) A refactored signaling pathway, consisting of a minimized set of signaling components for transmitting a unidirectional 
signal from the cell surface to the nucleus. Gauges and padlocks represent components we have chosen to vary or keep 
fixed, respectively. 
(D) The 15 gene deletions in the model strain, serving six key purposes; i) to remove negative feedback within the signaling 
pathway (SST2), ii) to prevent unwanted cell-cycle arrest (FAR1), iii) to prevent ɑ-factor signal degradation (BAR1), iv) to 
be refactored with synthetic tools (STE2, GPA1, STE4, STE18, and STE12), v) to remove mechanisms for pheromone-
based communication (MF(ALPHA)1+2, MFA1+2 and STE3), and vi) to remove all other instances of GPCR/G-protein 
signaling (GPR1 and GPA2). 
Tuning GPCR and G Protein Levels Alters Response Sensitivity and Basal Activity 
Previous work has shown that the sensitivity of the yeast pheromone response pathway can be 
changed by altering the receptor number in the absence of Sst2 (Bush et al., 2016). Basal activity 
from constitutive receptor activity can also be reduced by overexpressing Gɑ (Bakker et al., 2001; 
Burstein et al., 1997), as this acts as a negative regulator of signaling since Gβγ propagates the 
response to the MAPK cascade (Bardwell, 2004). Therefore, to explore how sensitivity and basal 
activity could be varied by altering expression of the GPCR, Gɑ, and Gβγ, we built a mathematical 
model derived from a previously-described cubic ternary complex model (Bridge et al. 2018), 
designing this to capture G protein signaling in our minimized pheromone response pathway (Figure 
2A). We then systematically probed the response of the pathway in this model by individually altering 
the initial GPCR, Gɑ, and Gβγ concentrations, while keeping all other components fixed (Figure 
2D+2E, Model). 
While this model demonstrated a clear monotonic relationship between receptor number, sensitivity 
and maximum signal, as previously shown by Bush et al. (2016), the relationship between Gɑ and 
Gβγ levels and pathway response was non-monotonic. At lower concentrations of Gɑ, constitutive 
activation of the pathway was observed due to increased free Gβγ. This, in combination with the 
incorrect trafficking and instability of Gβγ, due to low levels of Gɑ, leads to a lower maximum-fold 
change in activation (Hirschman et al., 1997; Song et al., 1996). At higher Gɑ concentrations, free 
Gβγ is rapidly sequestered, also leading to a decrease in the maximum fold change by acting as a 
“sponge” to signaling. A reverse behavior was seen when varying the initial concentration of Gβγ, with 
low concentrations decreasing maximum signaling and high concentrations leading to increased 
basal activity, albeit with a lower maximum signal, due to incorrect trafficking of free Gβγ, and 
therefore the Ste5 scaffold (Pryciak and Huntress, 1998). Taken together, the model predicts an 
optimal level of Gɑ and Gβγ expression where all three members of the heterotrimeric G protein are 
required to be in balance to give a high-fold change in signal upon activation. 
Next, using the model strain and modular cloning system, we experimentally validated the findings of 
the mathematical model using a minimized pheromone response pathway. This was constructed by 
refactoring the GPCR, Gɑ, Gβγ, and transcription factor so that these are expressed from constitutive 
promoters that we determined to give approximately the same expression of the native promoters in 
their uninduced state (Figure S2B-S2G). For the Gβγ component, we expressed both subunits 
together as a bicistronic protein (Ste4-2A-Ste18) where the self-cleaving 2A peptide releases 
equimolar amounts of the two proteins (Liu et al., 2017). The FUS1 promoter was used to express 
sfGFP as the response reporter (Figure S2H), enabling pathway activation to be measured by flow 
cytometry. With this strain, we then individually varied the expression of the GPCR, Gɑ, and Gβγ by 
changing their promoter strengths while keeping all other components fixed. This gave in vivo results 
that qualitatively matched the model, demonstrating tuneability of sensitivity by changing GPCR 
expression and revealing the predicted optimal levels of Gɑ and Gβγ that give the peak response 
(Figure 2D+2E, Experimental). As basal activity could be reduced by altering levels of either Gɑ or 
Gβγ, we decided to concentrate on Gɑ tuning, using a strain with fixed expression of Gβγ (yWS677) 
for all further experiments. 
Figure 2. Model-Guided Tuning for Optimal G Protein Signaling. 
(A) Cubic ternary complex model of G protein signaling in the minimized pheromone response pathway. 
(B) The minimized ɑ-factor signaling pathway. Binding of the ligand (ɑ-factor) to its specific GPCR (Ste2) on the cell surface 
leads to GDP-GTP exchange on the Gɑ subunit (Gpa1) and the release of the Gβγ dimer (Ste4 and Ste18), recruiting the 
MAP-kinase cascade to the membrane and facilitating the induction of the pathway via Ste20, ultimately resulting in the 
phosphorylation of the Ste12 transcription factor to induce gene expression via the pheromone responsive FUS1 promoter.  
(C) Promoter combinations used for refactoring Ste2, Gpa1, and Ste4-2A-Ste18. 
(D) ɑ-factor dose-response characteristics from individually varying the GPCR (green), Gɑ (blue), and Gβγ (grey) 
concentrations computationally and expression levels experimentally. 
(E) Analysis of dose-response characteristics, demonstrating trends in the expression profiles of the refactored signaling 
components. Sensitivity is defined as the lowest concentration to produce a 2-fold change in GFP expression over 
background. See Figure S3 for a quantitative plot of Ste2, Gpa1, and Ste4-2A-Ste18 expression vs pathway output. 
Experimental measurements are sfGFP levels per cell determined by flow cytometry and shown as the mean ± standard 
deviation from triplicate isolates. Curves were fitted using GraphPad Prism variable slope (four parameter) nonlinear 
regression fit. 
Modulating Signal Output by Refactoring the Ste12 Transcription Factor 
Next, we sought to modulate maximum pathway output by varying the expression of the pheromone-
responsive transcription factor, Ste12, as levels of transcription factor in a system often dictate gene 
expression strength (Brewster et al., 2014). However, increasing the expression of Ste12 led to poor 
cell growth, presumably by triggering high basal activity of mating response genes (Dolan and Fields, 
1990) (Figure S4A+S4B). We therefore needed a new means to tune pathway-mediated expression 
without changing Ste12 concentrations. 
By fusing the pheromone-responsive domain of Ste12 (PRD; 216-688) to the full-length LexA bacterial 
repressor protein (Mukherjee et al., 2015; Pi et al., 1997) we generated a synthetic transcription factor 
(sTF; LexA-PRD) able to target the pathway output to a library of modular synthetic promoters 
containing LexA operator sequences (LexO) (Figure 3C). We could then vary the recruitment of the 
LexA-PRD transcription factor by altering the number of operator sequences in the promoter upstream 
activating sequence (UAS), enabling us to modulate the maximum output of the response over a 
three-fold range without compromising the tightness of the OFF state (Figure 3D). Changing the 
identity of the core region of the promoter to alter the transcription initiation rate offers a further 
approach to tuning the output (Figure 3E). Externally tuning the activation of the synthetic promoters 
with chemical inducers was also made possible by fusing the PRD to ligand-inducible DNA binding 
domains (DBDs) (McIsaac et al., 2014; Urlinger et al., 2000) (Figure 3F-3K). Finally, we validated 
that the pheromone response pathway and the downstream mating response were now decoupled 
by this design, by demonstrating that native Ste12-regulated genes were no longer transcriptionally 
activated by pathway activity (Figure S4C). 
 
Figure 3. Modulating the Maximum Pathway Output Using Synthetic Transcription Factors. 
(A) The native pheromone-responsive transcription factor, Ste12, composed of a DNA binding domain (DBD; 1-215) and 
pheromone-responsive domain (PRD; 216-688), targets a mating response gene via the pheromone-response element 
(PRE). 
(B) sTFs are created from fusion of orthogonal DBDs and the Ste12 PRD which can then be targeted to synthetic promoters.  
(C) Fusion of the full-length bacterial LexA repressor with the Ste12 PRD controls the expression of a modular promoter 
with an interchangeable UAS and core promoter region, upstream of sfGFP. 
(D+E) Maximum ɑ-factor-activated pathway expression mediated by the LexA-PRD sTF driving the expression from 
synthetic promoter variants with UAS and core promoter modules modified, respectively. 
(F) Fusion of the TetR bacterial repressor with the Ste12 PRD, targets a synthetic promoter with 7 repeats of the TetO 
binding site and the minimal LEU2 promoter, driving aTc-repressible expression of sfGFP. 
(G) Inducing maximum ɑ-factor-induced expression of the TetR-PRD-mediated signaling pathway over a range of aTc 
concentrations. 
(H) ɑ-factor dose-response curve of the TetR-PRD-mediated pathway with and without aTc. 
(I) A fusion of the PRD to the Z3E transcription factor (itself a fusion of Zif268 DBD and the human estrogen receptor ligand 
binding domain) targets the pZ3 promoter (a modified GAL1 promoter with six Zif268 binding sites) (McIsaac et al., 2014) 
driving β-estradiol-conditional expression of sfGFP. 
(J) Inducing maximum ɑ-factor-induced expression of the Z3E-PRD-mediated signaling pathway over a range of β-estradiol 
concentrations. 
(K) ɑ-factor dose-response curve of the Z3E-PRD-mediated pathway with and without β-estradiol. 
Experimental measurements are sfGFP levels per cell determined by flow cytometry and shown as the mean ± standard 
deviation from triplicate isolates. Curves were fitted using GraphPad Prism variable slope (four parameter) nonlinear 
regression fit. 
Refactoring Enables Rational Optimization of Pheromone Sensing 
Together our mathematical and in vivo models reveal that although GPCR dose-response is the 
output of a complex system, variability can be achieved by altering the promoter identify for just three 
components (receptor, Gɑ, and reporter), offering a simple approach to rationally tune the sensitivity, 
basal activity, and signal output of a GPCR signaling pathway. To demonstrate this in practice, we 
next set out to optimize the ɑ-factor response of our minimized response pathway through iterative 
refactoring of these components. Our starting strain, with constitutive expression of the three 
components set at native levels (Figure 3A+3B, Design 1), performed poorly compared to the Quasi-
WT strain, which we hypothesized was due to removal of regulated expression of pathway 
components. Indeed, Ste2, Gpa1, and Ste12 all have Ste12-activated promoters and so benefit from 
positive feedback in their native setting (Paliwal et al., 2007). Guided by our model, we were able to 
restore performance by engineered reintroduction of Ste12-mediated feedback (Figure S4D-S4G), 
however we did not move forward with this design as it would couple sensitivity to pathway output. 
Instead, to improve on the performance of the Design 1 strain, we increased Gpa1 levels using the 
PGK1 promoter to reduce the basal activity of the response to effectively zero (Figure 3A+3B, Design 
2). The dose-response sensitivity could then also be boosted by increasing Ste2 expression via the 
strongest promoter available (pCCW12). This version (Figure 3A+3B, Design 3) now approached 
the sensitivity of the Quasi-WT strain for the ɑ-factor inducer and the physical limits of the receptor 
(Figure S4H). Finally, the output strength of the response could be maximized by linking the pathway 
to activate the best performing synthetic promoter, LexO(6x)-pLEU2m, via the LexA-PRD sTF (Figure 
3A+3B, Design 4). The resulting pathway was highly optimized in comparison to the Quasi-WT strain 
with improved operational range, tightness, dynamic range, and maximum output. Notably, this is 
achieved without the need for feedback regulation of signaling components and also offers a pathway 
decoupled from the >100 genes usually upregulated in the mating response (Roberts et al., 2000). 
Furthermore, the engineering we had performed to the Design 4 strain had come with no penalty to 
the growth rate when compared to wild type or Quasi-WT yeast (Figure S4I-J). 
Understanding how the pathway dose-response can be shifted in this manner advances our basic 
knowledge of how component level changes effect signal transduction. Alongside this, it also offers 
direct applications for synthetic biology, where reprogramming cells to receive specific signals and 
respond in a desired manner is a core goal (Brophy and Voigt, 2014). Indeed, GPCRs represent the 
ideal sensory module for eukaryotic synthetic biology as they are responsive to a plethora of ligands 
and stimuli, often operate with high specificity (Heng et al., 2014), and naturally have modularity 
written into their signaling architecture (Andrianantoandro et al., 2006; Katritch et al., 2012). 
With this in mind, we set out to establish our model strain as a host cell for rationally engineering 
yeast as sensors that detect diverse inputs via heterologous GPCRs (see Figure S5 for a description 
of the final toolkit). As an initial demonstration we took the Mam2 receptor from Schizosaccharomyces 
pombe, which detects a 23 amino acid peptide pheromone called P-factor (Ladds et al., 2005b). Using 
the optimized tuning levels determined for Design 4, we generated a P-factor-sensing strain in less 
than a week. We then compared the response of this sensor strain to the response observed in its 
native context, as reported by Croft et al. (2013) (Figure 3D). The Mam2 sensor strain behaved almost 
exactly as in S. pombe, achieving an identical potency (EC50) to P-factor. Furthermore, the Mam2 
sensor strain displayed no detectable basal activity and exhibited a 180-fold change in signal after 




Figure 4. Tuning the Minimized Response Pathway Through Iterative Refactoring. 
(A) ɑ-factor dose-response curves for the 4 sequential minimized pathway designs compared to the Quasi-WT response.  
(B) Dose-response characteristics for the 4 minimized pathway designs compared to Quasi-WT. Tightness is defined as the 
reciprocal of basal activity and the dynamic range is defined as (maximum output/basal activity). Sensitivity and operational 
range were determined from the fitted curve, defining sensitivity as the lowest concentration for which a >2-fold change in 
GFP expression is seen, and operational range as the concentration span between the sensitivity and the lowest 
concentration that gives a GFP expression within 2-fold of the maximum. All values were then normalized to the minimum 
measurable value and the maximum calculated value in the dataset. 
(C) Domesticating the S. pombe Mam2 receptor in yWS677. The conditions identified during the 3-week optimization of the 
ɑ-factor response with Ste2 receptor were directly applied to the design of the Mam2 sensor strain, enabling construction in 
less than a week. 
(D) P-factor dose-response curves of the Mam2 sensor (light blue) compared to the wild-type Mam2 response in its native 
S. pombe background (black) using previously obtained data from Croft et al. (2013). Slight differences in curve shape are 
likely due to differences in assay length and choice of reporter. 
Experimental measurements are sfGFP levels per cell determined by flow cytometry and shown as the mean ± standard 
deviation from triplicate isolates. S. pombe Mam2 dose-response taken from Croft et al. (2013) and represents P-factor-
dependent transcription of β-galactosidase using the sxa2 promoter, taking measurements 16 hours after stimulation. 
Curves were fitted using GraphPad Prism variable slope (four parameter) nonlinear regression fit. 
 
Engineered Consortia for Extending and Narrowing Operational Range 
Efforts to create sensor strains over the last two decades have coupled heterologous GPCRs to the 
yeast pheromone response pathway with varying success. Now with the approach described here, 
the sensitivity, basal activity, and response output of cells sensing via heterologous GPCRs can be 
rationally tuned. However, one further important characteristic of a sensor - its operational range (the 
Hill slope of its dose-response curve) - is more difficult to adjust, as it is determined largely by the 
ligand-binding properties of the receptor. Some receptors will confer a narrow range switch-like 
behavior, only requiring a small increase in signal to trigger maximum output (i.e. a digital response), 
whereas others will give a wide operational range where there is a proportional relationship between 
signal and output (i.e. a linear response) (Dueber et al., 2007). For sensor applications, a linear 
response is typically required, whereas the digital response is more desirable for point-of-care and 
gene circuit applications. 
Given these considerations, we next set-out to solve how the operational range can also be tuned 
using an engineering approach, so that the Hill slope can be reduced to expand an operational range, 
or the Hill slope can be increased to narrow an operational range. For this we first built two new sensor 
strains, both sensing medically-relevant metabolites by having human GPCRs coupled to our 
refactored yeast pathway. The chosen receptors were the adenosine-responsive A2BR receptor, 
previously shown to give a digital-like response in yeast (Beukers, 2004), and the melatonin-
responsive MTNR1A receptor, previously shown to give a linear-like response in yeast (Kokkola et 
al., 1998) (Figure S6A-S6D). 
While previous efforts have tuned the yeast pheromone response Hill slope by overlaying synthetic 
feedback loops into the MAPK cascade (Bashor et al., 2008; Galloway et al., 2013; Ingolia and 
Murray, 2007), feedback loops on the components tuned in our approach proved ineffective in 
changing the dose-response curves (Figure S6E-S6L), likely because our orthogonal sTFs do not 
have the autoregulatory feedback that Ste12 has via its native promoter (Paliwal et al., 2007). Without 
this avenue, we instead choose a different tactic; tuning the Hill slope by creating engineered 
communities of cells that change the average response at the population level. 
Firstly, to create a population that linearizes the steep response curve of our adenosine-sensing cells, 
we took inspiration from a strategy employed by previous artificial sensor systems, where receptors 
with different sensitivities are combined and their average response determines the output (Vallée-
Bélisle et al., 2012). We used rational tuning of GPCR levels to create two new strains with increased 
and decreased sensitivity to adenosine, and then tuned the output promoters so that their maximum 
outputs match (Figure 5A), using total fluorescence of each culture to measure GFP output (Figure 
S7A+S7B). We then co-cultured the three-sensing strains in a 1:1:1 ratio to create a consortium 
whose average response integrates the signal from all cells to give an extended operational range. 
This almost halved the Hill slope of the response while maintaining a similar potency, yielding an 
operational range 50-fold greater than the initial response (Figure 5B+5C). 
Narrowing the operational range of the melatonin-responsive MTNR1A sensor strains required more 
complex engineering as the Hill slope of a response can only be increased via mechanisms such as 
cooperativity (Dueber et al., 2007), sequestration (Buchler and Louis, 2008), or positive feedback 
(Ferrell, 2002). As before, we utilized a community-based approach, but here using cell-to-cell 
communication to enable feedback at the population level (Groß et al., 2011; Urrios et al., 2016). A 
two-cell system was designed where the first cell acts as an amplifier, sensing via MTNR1A and 
responding by secreting ɑ-factor from the reintroduced gene. The second cell senses ɑ-factor and 
responds with reporter gene (sfGFP) expression, and also secretes constitutive levels of the ɑ-factor 
degrading protease, Bar1, to create a threshold for activation (Figure 5D+5E). 
Computational modelling revealed that fine-tuning Bar1 levels was important for a generating a steep 
Hill slope while maintaining tightness and high dynamic range, albeit with some loss of sensitivity 
(Figure S7C). To determine the optimal expression of Bar1, we tested a range of promoters and 
measured the dose-response of the two-cell system. The RPL18B promoter emerged as ideal choice 
for driving Bar1 expression as it eliminated basal activity in the two-cell amplifier-reporter system while 
also maintaining high levels of maximum signal (Figure S7D). 
Following the creation of the ɑ-factor-detecting reporter cells and the tuning of Bar1 levels secreted 
by these, we engineered the digital response in two steps using our toolkit (Figure S7F-S7H). 
Amplifier cells were first created by linking the output of MTNR1A sensor strain to the production of 
peptide pheromone, ɑ-factor. The sensitivity of these cells was then tuned by adjusting MTNR1A 
receptor expression in the amplifier strain, so that the potency of the response in the two-cell system 
matched that of the single cell version. When co-cultured in a 1:1 ratio, the final tuned two-cell system 
maintained the same potency but now provided a dose-response curve with a 2.3-fold increase in Hill 
slope and more than 200-fold decrease in the operational range (Figure 5F+5G). 
 
Figure 5. Engineered Consortia for Tuning the Operational Range of Heterologous GPCR Sensors. 
(A) Engineered cells combined to produce a system with an extended operational range. First, a range of cells are produced 
with different sensitivities to a ligand by expressing the GPCR at different levels. Next, the ligand responses are tuned to 
produce equivalent maximum outputs. Finally, the cells are combined in equal parts to create a mixed population of cells 
whose average expression has an extended operational range. 
(B) The dose-response of the human A2BR receptor to adenosine in a single yeast strain, operational over 1.6 orders of 
magnitude. 
(C) The extended dose-response of a consortia of three engineered strains, operational over 3.3 orders of magnitude. 
(D) A mixed population of yeast strains engineered as amplifier and reporters is designed to create a digital response from 
an otherwise linear sensor. In response to ligand, amplifier cells release ɑ-factor which is detected by reporter cells 
constitutively secreting the ɑ-factor degrading protease, Bar1. The presence of Bar1 degrades low levels of ɑ-factor 
preventing reporter strain activation until levels of ɑ-factor are high enough to saturate the capacity of Bar1-mediated 
degradation. 
(E) Computational model of the amplifier-reporter system response to increasing ligand (L) with Bar1-mediated threshold 
response included. 
(F) The broad dose-response of the human MTNR1A receptor to melatonin, operational over 3.8 orders of magnitude. 
(G) Digitized melatonin sensing with the two-strain system, operational over 1.5 orders of magnitude. 
Operational range is defined as the concentration span between 5% and 95% of the activated response. Experimental 
measurements are sfGFP levels determined by a plate reader and shown as the mean ± standard deviation from triplicate 
isolates. Curves were fitted using GraphPad Prism variable slope (four parameter) nonlinear regression fit. 
Yeast GPCR Sensors for Metabolite Quantification and Pathogen Detection 
The ability to rationally tune all dose-response properties for GPCR-signaling enables yeast strains 
to be optimized as sensors appropriate for different types of applications. To demonstrate this, we 
tackled two different example cases; metabolite quantification, where specificity and a wide dynamic 
range are desired, and point-of-care pathogen detection, where a sensitive digital-like response is 
needed. 
Germann et al. recently reported production of melatonin from S. cerevisiae by constructing a 
biosynthetic pathway that converts L-tryptophan into melatonin via three non-native intermediates 
(Germann et al., 2016). We thus sought to create sensor strains optimized for measuring melatonin 
production from these engineered yeast, exploiting the fact that our MTNR1A sensor strains 
demonstrate exquisite specificity for melatonin over its precursors (Figure 6A). 
To enable quantification of melatonin from our strains we engineered a two-strain consortia to widen 
the operational range to match the range of melatonin concentrations reported by Germann et al. from 
their production strains (Figure 6B). The resulting curve was linear over four orders of magnitude. 
We harvested supernatant from 88 different melatonin producer strains from the previous study, and 
in parallel measured melatonin levels with our consortia of sensor strains and by liquid 
chromatography-mass spectrometry (LC-MS) (Figure 6C+6D). The calculated concentrations of 
melatonin determined by the two methods agreed strongly, with the yeast sensor arguably more 
accurate over the large span of concentrations, due to the known limitations of the linear range in LC-
MS measurement (Gika et al., 2014). 
For pathogen detection, we next set out to tune a point-of-care sensor for Paracoccidioides 
brasiliensis, recently developed by Ostrov et al. (2017). This yeast GPCR-based sensor, utilizing the 
Ste2 homolog from P. brasiliensis (PbSte2), detects environmental levels of pheromone peptide 
released by haploid P. brasiliensis cells (PbPeptide) as a means of specifically detecting this human 
pathogen in complex samples (Figure 6E). This receptor exhibits a wide operational range with 
nanomolar sensitivity in S. cerevisiae (Ostrov et al., 2017) but a digital “yes/no” response would be 
more appropriate for point-of-care use, as would greater sensitivity. To optimize these two properties, 
we applied our amplifier-receiver two strain approach to the PbSte2 sensor (Figure 6F-6H). 
Increasing receptor levels with the CCW12 promoter and incorporating signal amplification created a 
consortia that now detected in the picomolar range, reporting with a digital-like response due to an 
operational range now narrowed by 1000-fold. 
 
 
Figure 6. Applications of Tunable Yeast GPCR Sensor Strains. 
(A) Selectivity of the MTNR1A sensor strain to melatonin and intermediates in the melatonin biosynthesis pathway from 
Germann et al., 2016. 
(B) A linearized MTNR1A sensor population consisting of two strains with different sensitives to linearize the dose-response 
of melatonin sensing in the range of concentrations appropriate for microbial production as reported by Germann et al.  
(C) Measuring the production of melatonin from the spent media of 88 different yeast producer strains using the MTNR1A 
sensor consortia and LC-MS. 
(D) The measured production of melatonin from the 88 producer strains, from Germann et al., as determined from 
measurements from the sensor consortia and LC-MS. A linear y=x curve was fitted to the dataset. 
(E) Detection of the P. brasiliensis pheromone peptide (PbPeptide) using the P. brasiliensis Ste2 homologue (PbSte2).  
(F+G) PbPeptide dose-response of the single cell PbSte2 sensor compared to the two-cell amplifier-receiver consortia.  
(H) Potency (logEC50), Hill slope, and operational range values of the single and mixed cell populations compared to data 
from Ostrov et al. 
Experimental measurements are sfGFP levels per cell determined by flow cytometry (A-D) and GFP levels determined by a 
plate reader (E-H) and shown as the mean ± standard deviation from triplicate isolates. Curves were fitted using GraphPad 
Prism variable slope (four parameter) nonlinear regression fit. 
See Table S1 for a list of GPCRs shown to functionally couple in S. cerevisiae that could be used for sensor applications. 
DISCUSSION 
In this study, we used genome engineering and synthetic biology tools to refactor a minimal GPCR 
signaling pathway so that it could be rationally tuned both in silico and in vivo. This revealed three key 
design principles for tuning the signaling pathway dose-response curve: i) sensitivity is increased by 
increasing GPCR numbers, ii) basal activity is reduced by finding the G protein expression optima, 
and iii) amplitude (pathway output) is tunable via synthetic transcription factors and engineered 
promoters. With these principles we were able to engineer yeast strains for desired performance as 
sensors for peptide inducers, and for primary and secondary metabolites. 
Uncovering these principles was achieved here by the close connection between in silico modelling 
and experimental validation. This was made possible by refactoring yeast into a strain that effectively 
acts as an in vivo model, with component expression levels that can be individually varied, and 
performance simple to measure via fluorescent output. The in silico model allowed us to first 
understand where component level tuning has the greatest impact on the signaling response, with 
experimental work then confirming this and identifying the promoters that will achieve these levels in 
subsequent engineering. 
As well as confirming past observations on signaling stoichiometry, the model also revealed a 
complex, non-monotonic relationship between G protein subunit levels and pathway activity. An 
unexpected decrease in the response maximum output was predicted by the model for low Gɑ or high 
Gβγ levels, with this confirmed by experiments. By modeling different mechanisms, we were able to 
attribute this reduced activity to incorrect trafficking of Gβγ in the absence of free Gɑ. This insight told 
us that fine-tuned expression of G protein subunits would be essential for signal transduction that has 
minimal basal activity but maintains a high output when activated. 
Varying signaling component stoichiometries in our in silico and in vivo work also demonstrated that 
the GPCR-mediated response is not merely defined by the receptor’s intrinsic properties (i.e. ligand 
affinity); instead it is a function of the properties of all components in the signaling pathway and 
particularly their relative levels. This fact has important consequences. It explains how signal 
transduction behavior could be significantly altered by a change in component levels, whether due to 
a change in environmental conditions or due to altered expression and protein turnover, for example 
in different tissues. Indeed, via this mechanism cells can have different sensitivities and activation 
thresholds for the same agonist while expressing identical receptors. Importantly, this fact also 
underlines why non-coding genetic variation, such as mutation in promoter regions, has to also be 
considered alongside protein polymorphisms when assessing how genetic variation links to health 
and to the efficacy of treatments (Ward and Kellis, 2012). Already, receptor variation in humans is 
recognized as a major cause of GPCR-targeting drugs being ineffective in many individuals (Hauser 
et al., 2018), and it is possible that non-coding mutations that alter pathway stoichiometries could 
further explain such cases. 
We anticipate that the tuning principles uncovered here in yeast will also be relevant for GPCR 
signaling in all eukaryotes, however, it is worth re-stressing the large diversity in the type and structure 
of downstream signaling pathways paired with GPCRs in different organisms and cell types. The next 
steps for our approach will therefore be to use equivalent tools to refactor a canonical mammalian 
GPCR pathway so that its components can be tuned and assessed in isolation to the point where the 
dose-response to the agonist can be set as desired. This would also accelerate applications in 
pharmacology and healthcare that utilize GPCRs, such as in cell-based theranostics where cells are 
engineered to detect and act upon receiving defined cues within the human body (Heng et al., 2014).  
While mammalian systems remain the go-to choice for studying GPCR activity, the genetic 
amenability, ease of use, and low cost make yeast an ideal organism for many sensor applications 
(Adeniran et al., 2014; Blount et al., 2012; Jarque et al., 2016; Ladds et al., 2005a). As demonstrated 
here, our model strain offers immediate applications for engineering yeast to sense its environment, 
whether as single strains or in engineered consortia. Already efforts in synthetic biology have used 
engineered yeast sensors as medical diagnostics (Adeniran et al., 2018), for pathogen detection 
(Ostrov et al., 2017), and as a tool for accelerating metabolic engineering (Ehrenworth et al., 2017; 
Mukherjee et al., 2015). In all these applications, it is desirable for the user to have control over the 
response to input and the magnitude of gene expression it triggers. Full ability to tune sensors, as 
shown here, allows engineering for desired detection windows, and could be used in further work to 
define thresholds for activation (e.g. for directed evolution (Adeniran et al., 2018; Dong et al., 2010)) 
or for matching the input/output levels when cells are engineered to detect and act, or to communicate 
in connected systems (Billerbeck et al., 2018). 
A current limitation of using yeast as sensors is that most medically-relevant GPCRs do not port 
directly into S. cerevisiae without requiring optimization of expression, membrane translocation, and 
pathway coupling (Sarramegna et al., 2003). Co-expression of mammalian accessory proteins 
(Fukutani et al., 2015) and the humanization of the yeast membrane (Routledge et al., 2016) have 
also been shown to improve porting of receptors from mammalian species, and at the last count at 
least 50 different foreign GPCRs have been demonstrated to function in yeast (Table S1). These past 
successes provide a guide for those looking to generate yeast sensors for ligands and metabolites. 
However, without further experimental testing there are no guarantees that they will behave as 
required. In particular, the specificity of the receptor for the intended ligand is a major consideration 
as many receptors are promiscuous in what they bind. Another consideration is whether the ligand of 
interest can easily access a GPCR on the yeast cell membrane, especially given that yeast has a 
primitive cell wall. Fortunately for extracellular metabolite sensing, the porous structure of the cell wall 
is less of a concern, as it allows the free passage of molecules as large as 800 kDa (De Nobel and 
Barnett, 1991).  
Our model strain now offers a new starting point for the many applications of GPCR-sensing enabling 
further work in a systematic, plug-and-play manner. Our overall strategy, of simplifying and refactoring 
a natural pathway to first understand it and then rationally expand it, should also be applicable to 
other systems in and beyond signal transduction. With the accelerating capabilities of genome 
engineering and synthetic biology in all organisms, it is likely that we will see the creation of equivalent 
in vivo model strains to rationally explore and exploit the key features and parameters of other 
important biological systems. 
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CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, 
Tom Ellis (t.ellis@imperial.ac.uk). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Bacterial Strains and Growth Media 
NEB® Turbo Competent E. coli was used for all cloning experiments. Selection and growth of E. coli was performed in 
Lysogeny Broth (LB) medium at 37 °C with aeration. With the exception of generating competent cells, the LB medium was 
supplemented with appropriate antibiotics (ampicillin 100 μg/mL, chloramphenicol 34 μg/mL, or kanamycin 50 μg/mL).  
 
Yeast Strains and Growth Media 
For a list of all yeast strains used in this study see Key Resource Table. Apart from BY4741, all strains used in this study 
are a derivative of the yWS677 model strain (sst2Δ0 far1Δ0 bar1Δ0 ste2Δ0 ste12Δ0 gpa1Δ0 ste3Δ0 mf(alpha)1Δ0 
mf(alpha)2Δ0 mfa1Δ0 mfa2Δ0 gpr1Δ0 gpa2Δ0), which is itself a derivative of BY4741 (MATɑ his3Δ1 leu2Δ0 met15Δ0 
ura3Δ0). The yWS677 model strain was generated using iterative markerless CRISPR/Cas9 genome engineering (see 
Methods Details). Further editing of yWS677 to create the additional strains was performed in a single step using 
markerless CRISPR/Cas9 genome engineering. 
Yeast extract peptone dextrose (YPD) was used for culturing cells in preparation for transformation: 1% (w/v) Bacto Yeast 
Extract (Merck), 2% (w/v) Bacto Peptone (Merck), 2% glucose (VWR). Cells were cultured at 30 °C shaking at 250 rpm. 
Selection of yeast transformants was performed on synthetic complete (SC) dropout agar medium: 2% (w/v) glucose (VWR), 
0.67% (w/v) Yeast Nitrogen Base without amino acids (Sigma), 0.14% (w/v) Yeast Synthetic Drop-out Medium Supplements 
without histidine, leucine, tryptophan, and uracil (Sigma) supplemented with 20 mg/L tryptophan (Sigma), and 20 g/L 
bacteriological agar (VWR). Depending on the required selection, SC dropout media was supplemented with 20 mg/L uracil 
(Sigma), 100 mg/L leucine (Sigma), and 20 mg/L histidine (Sigma). Cells were grown at 30 °C static. 
All liquid experiments were performed in synthetic complete (SC) medium with 2% (w/v) glucose (VWR), 0.67% (w/v) Yeast 
Nitrogen Base without amino acids (Sigma), 0.14% (w/v) Yeast Synthetic Drop-out Medium Supplements without histidine, 
leucine, tryptophan, and uracil (Sigma), 20 mg/L uracil (Sigma), 100 mg/L leucine (Sigma), 20 mg/L histidine (Sigma), and 
20 mg/mL tryptophan (Sigma). Unless otherwise stated, all yeast strains were cultured in 500 μL of SC medium and grown 




Chemically competent cells were created following the TSS protocol for KCM transformations (Chung et al., 1989). A colony 
of E. coli was grown to saturation overnight in 10 mL of LB and then split into two 2 L baffled flasks with 500 mL of LB. The 
culture was grown for 2-3 h to OD600 ~ 1.0, chilled on ice to stop growth, split between 50 mL conical tubes, and centrifuged 
at 4000 rpm at 4 °C for 10 minutes. The supernatant was then discarded, and the cell pellets resuspended by aspiration in 
ice-cold TSS (85 mL LB, 10 g PEG-3350, 5 mL DMSO, and 2 mL 1 M MgCl2). 200 μL of the cell suspension was then 
aliquoted into PCR reaction tubes, flash frozen on dry ice, and put into a -80 °C freezer for long term storage. To transform 
the DNA, 50 μL of 5 x KCM (500 mM KCl, 150 mM CaCl2, 250 mM MgCl2) was added to 200 μL of the competent cell prep 
after 10 minutes for thawing on ice. 50 μL of the competent cell-KCM cocktail was then added to DNA and transferred to a 
thermocycler with the following protocol: 4 °C for 10 minutes, 42 °C for 1 minute, 4 °C for 1 minutes, and then 30-60 minutes 
recovery at 37 °C. Cells were then plated on solid LB medium supplemented with the appropriate antibiotics. 
 
Yeast Transformations 
Chemically competent yeast cells were created following the lithium acetate protocol (Gietz and Schiestl, 2007). Yeast 
colonies were grown to saturation overnight in YPD. The following morning the cells were diluted 1:100 in 15 mL of fresh 
YPD in a 50 mL conical tube and grown for 4-6 h to OD600 0.8-1.0. Cells were pelleted and washed once with 10 mL 0.1 
M lithium acetate (LiOAc) (Sigma). Cells were then resuspended in 0.1 M LiOAc to a total volume of 100 μL/transformation. 
100 μL of cell suspension was then distributed into 1.5 mL reaction tubes and pelleted. Cells were resuspended in 64 μL of 
DNA/salmon sperm DNA mixture (10 μL of boiled salmon sperm DNA (Invitrogen) + DNA + ddH2O), and then mixed with 
294 μL of PEG/LiOAc mixture (260 μL 50% (w/v) PEG-3350 (Sigma) + 36 μL 1 M LiOAc). The yeast transformation mixture 
was then heat-shocked at 42 °C for 40 mins, pelleted, resuspended in 200 μL 5 mM CaCl2 and plated onto the appropriate 
synthetic dropout medium. 
 
Iterative Markerless Editing of Yeast Genome 
All genomic edits were performed via CRISPR/Cas9, using a two-plasmid system, consisting of a gRNA expression plasmid 
(pWS082) and a CRISPR/Cas9 expression plasmid with the choice of three different selection markers (pWS158, URA3; 
pWS171, LEU2; pWS172, HIS3). This system supplies Cas9 and gRNAs on two different plasmids, which are first linearized 
and then gap repair with each other in yeast to create single plasmid which contains both components. For multiplexing 
edits, multiple gRNA fragments can be introduced into yeast simultaneously. Individual gRNAs were expressed using the 
format used in the YTK system (Lee et al., 2015), whereby a tRNA promoter drives the expression of a tRNA and HDV 
ribozyme fused to the 5’ of the gRNA followed by the SNR52 terminator. Cas9 is then expressed using the PGK1 promoter 
and terminator. To prepare the two plasmids for transformation, the CRISPR/Cas9 and gRNA expression plasmids were 
first digested with BsmBI or EcoRV, respectively, and the following size fragments were gel purified: pWS082, 1022 bp; 
pWS158, 10051 bp; pWS171, 10909 bp; pWS172, 10102 bp. 
New gRNA targets were designed in Benchling (www.benchling.com) using the CRISPR tool. gRNA sequences were then 
created using two annealed 26 bp oligonucleotides and assembled into the gRNA expression vector using a BsmbI Golden 
Gate assembly using the (GACT) overhang at the 5’ and (GTTT) at the 3’. An additional (TT) was included between the 5’ 
overhang and gRNA sequence to complete the HDV ribozyme sequence: 
5’ GACTTTNNNNNNNNNNNNNNNNNNNN 3’ 
3’     AANNNNNNNNNNNNNNNNNNNNCAAA 5’ 
Oligonucleotides were assembled into the pWS082 gRNA entry vector using the following protocol: Oligonucleotides were 
first resuspended at 100 μM concentration in H2O. Each oligonucleotide was then treated separately with T4 polynucleotide 
kinase (PNK) in the following reaction: 1 μL oligonucleotide (100 μM), 1 μL 10 x T4 DNA ligase buffer (Promega), 0.5 μL T4 
PNK (NEB), and 7.5 μL H2O. The mixture was then incubated at 37 °C for 1 hour. The 10 μL reactions for both 
oligonucleotides in the fragment pair were then added together and brought to a total volume of 200 μL in H2O (10 μL oligo 
(sense) + 10 μL oligo (antisense) + 180 μL H2O). The oligonucleotides were then annealed under slowly decreasing 
temperatures using the following programme: 96 °C for 6 minutes followed by 0.1 °C/s ramp down to 20 °C, and then hold 
at 20 °C. The resulting fragment was then ligated into the gRNA expression vector using Golden Gate assembly, which was 
prepared as follows: 0.1 μL of pWS082 (50 fmol/ μL), 1 μL of the small fragment, 1 μL T4 DNA ligase buffer (Promega), 0.5 
μL T7 DNA Ligase (NEB), 0.5 μL BsmBI (NEB), and water to bring the final volume to 10 μL. Reaction mixtures were then 
incubated in a thermocycler using the following program: (42 °C for 2 min, 16 °C for 5 min) x 10 cycles, followed by a final 
digestion step of 60 °C for 10 min, and then heat inactivation at 80 °C for 10 min. The entire reaction mixture was then 
transformed directly into E. coli and plated on LB medium with ampicillin (100 μg/mL). For a list of oligonucleotides used to 
create the gRNA sequences in this study, see Table S2. 
To edit the targeted regions, donor DNA was introduced into yeast alongside the CRISPR DNA to facilitate homology-
directed repair at the double-strand break. Donor DNA was created by first cloning the sequence into the pYTK001 part 
entry vector. Donor DNA consisted of 500 bp arms of homology flanking a unique 24 bp sequence containing a new 
CRISPR/Cas9 target (landing pad), which were designed using the Benchling CRISPR tool to have an off-target score of 
100 and a high on-target score. The plasmid was then sequence verified and primers were designed to amplify the donor 
DNA from the plasmid. The 1024 bp PCR amplicon was then gel purified to generate the donor DNA for transformation. For 
more information on donor DNA design see Figure S1A. For a list of landing pad sequences at the edited loci in the yWS677 
and yWS1922 model strains, see below. 
 












































































Reagents for CRIPSR markerless genome editing were prepared as follows: 50 ng of linear CRISPR/Cas9 plasmid, 500 ng 
of each linearized gRNA expression plasmid, and 1000 ng of each donor DNA. The DNA was then transformed directly into 
yeast and plated on the appropriate selective media. Edits were validated by colony PCR followed by sanger sequencing of 
the amplified genomic region (for a list of primers used in this study, see Table S2). To rapidly iterate between successive 
edits when generating the model strain, yWS677, a marker cycling protocol was used, where two deletions or changes were 
performed per round of editing. Plasmid curing was skipped, and the marker for selecting the CRISPR/Cas9 plasmid was 
cycled between 3 markers (URA3, LEU2, and HIS3) for each iteration. The final edit was performed with CRISPR/Cas9 
plasmid containing the URA3 selection marker, which was counter selected using 5-FoA to cure the yeast of CRISPR 
machinery (Figure S1B+S1C). The absence of all CRISPR/Cas9 plasmids was validated by colony PCR and replica plating 
on selective media. 
 
Nanopore Sequencing of the yWS677 Genome 
DNA was isolated from yWS677 for Nanopore sequencing using the 100/G Genomic-Tip kit (QIAGEN), sheared to 20 kb 
using a g-TUBE (Covaris) and prepared for sequencing using a Ligation Sequencing Kit 1D2 R9.5 (Oxford Nanopore 
Technologies). The genomic DNA was then run on an R9.5 flow cell using a MinION Mk 1B (Oxford Nanopore Technologies). 
A standard 48h sequencing run was performed using the MinKnow 1.5.5 software using local basecalling. Reads were 
exported directly to fastq using MinKNOW. Canu (v1.5) was used to correct raw reads (www.canu.readthedocs.io) and 
smartdenovo (www.github.com/ruanjue/smartdenovo) was used to de novo assemble the reads into contiguous sequences 
(contigs) using default flags. Resulting contigs were compared to a WT reference genome (s288c, SGD) using lastdb/lastal 
(www.last.cbrc.jp) and viewed on integrative genome viewer (IGV) (www.software.broadinstitute.org) to inspect genomic 
changes. We then probed all discrepancies between the yWS677 genome and the S288C reference using a minimum 
alignment length of 100 bp. 
 
Growth Curves 
Single colonies were grown to saturation overnight in 3 mL YPD. The next day, the yeast cultures were back diluted to an 
OD600 of 0.175, and 200 µL was transferred to a 96-well clear, flat-bottom microplate (Corning). OD600 was the measured 
over 24 h by a Synergy HT Microplate Reader (BioTek) taking measurements every 15 minutes with shaking at 30 °C in 
between readings. Growth rate per hour was calculated according to Equation 1, where t is time in hours. 
(Equation 1) 
(𝑙𝑛 𝑂𝐷600(𝑡 + 3ℎ)𝑂𝐷600(𝑡) )/3 
 
Plasmid Construction 
All plasmids within this study were created using the MoClo Yeast Toolkit (YTK) system (Lee et al., 2015). Additional 
sequences not included within the YTK system that were used within this study can be found in the Table S3. For a list of 
all plasmid constructs used in this study, see Table S4. Unless indicated, part sequences were either mutated or synthesized 
to remove or avoid all instances of the BsmBI, BsaI, BpiI, and NotI recognition sequences. 
Construction of all plasmid constructs in Table S4 was achieved using Golden Gate assembly. All parts were set to 
equimolar concentrations of 50 fmol/μL (50 nM) prior to experiments. Golden Gate reactions were prepared as follows: 0.1 
μL of backbone vector, 0.5 μL of each plasmid, 1 μL T4 DNA ligase buffer (Promega), 0.5 μL T7 DNA Ligase (NEB), 0.5 μL 
restriction enzyme (BsaI or BsmBI) (NEB), and water to bring the final volume to 10 μL. Reaction mixtures were then 
incubated in a thermocycler using the following program: (42 °C for 2 min, 16 °C for 5 min) x 25 cycles, followed by a final 
digestion step of 60 °C for 10 min, and then heat inactivation at 80 °C for 10 min. The entire reaction mixture was then 
transformed directly into E. coli and plated on LB medium with the appropriate antibiotics. 
 
Creation of the Gɑ Variant Library 
G protein c-terminal variants were created by substituting the GFP dropout cassette in the pWS936 Gpa1 C-terminal 
truncation vector for a small DNA fragment consisting of two annealed oligonucleotides. To create the small DNA fragment, 
oligonucleotides were first resuspended at 100 μM concentration in H2O. Each oligonucleotide was then treated separately 
with T4 polynucleotide kinase (PNK) in the following reaction: 1 μL oligonucleotide (100 μM), 1 μL 10 x T4 DNA ligase buffer 
(Promega), 0.5 μL T4 PNK (NEB), and 7.5 μL H2O. The mixture was then incubated at 37 °C for 1 hour. The 10 μL reactions 
for both oligonucleotides in the fragment pair were then added together and brought to a total volume of 200 μL in H2O (10 
μL oligo (sense) + 10 μL oligo (antisense) + 180 μL H2O). The oligonucleotides were then annealed under slowly decreasing 
temperatures using the following programme: 96 °C for 6 minutes followed by 0.1 °C/s ramp down to 20 °C, and then hold 
at 20 °C. The resulting fragment was then ligated into the Gpa1 C-terminal truncation vector using Golden Gate assembly, 
which was prepared as follows: 0.1 μL of pWS936 (50 fmol/ μL), 1 μL of the small fragment, 1 μL T4 DNA ligase buffer 
(Promega), 0.5 μL T7 DNA Ligase (NEB), 0.5 μL BsmBI (NEB), and water to bring the final volume to 10 μL. Reaction 
mixtures were then incubated in a thermocycler using the following program: (42 °C for 2 min, 16 °C for 5 min) x 10 cycles, 
followed by a final digestion step of 60 °C for 10 min, and then heat inactivation at 80 °C for 10 min. The entire reaction 
mixture was then transformed directly into E. coli and plated on LB medium with chloramphenicol (34 μg/mL) For a list of 
oligonucleotides used to create the G protein library, see Table S2. 
Multiplexed Yeast Plasmid Integrations 
The yWS677 model strain was prepared for multiplex integration of selectable plasmids by integrating landing pads (LPs) 
at the URA3, LEU2, and HO loci, conforming to the YTK integration plasmid format. Transient expression of Cas9 and the 
gRNAs targeting the landing pads was achieved by individually assembling Cas9 (pTDH3-Cas9-tTDH1) and the gRNAs 
(created using the YTK050 sgRNA dropout) into cassette plasmids without a yeast marker or yeast replicon. Single, double, 
and triple integration of marker plasmids were performed with 50, 100, and 200 ng of plasmid, respectively, with 100 ng of 
the Cas9 expression cassette and 200 ng of each gRNA expression cassette. All plasmids were first linearized by digestion 
before transformation using NotI-HF (NEB). Successful plasmid integration was selected for using synthetic drop-out media 
missing the appropriate supplements. Cas9 and gRNA expression was transient and quickly lost due to lack of selection or 
flanking homology to genome. Initially validated by colony PCR and then assumed thereafter. 
 
RT-qPCR 
All quantitative PCR (qPCR) reactions were performed in an MasterCycler ep realplex 4 (Eppendorf) using SYBR FAST 
Universal qPCR Master Mix (Kapa Biosystems). For RNA purification, RNA was isolated from yeast culture grown to an 
OD600 of 1 ± 0.1 using a YeaStar RNA Kit (Zymo Research). RNA was quantified by nanodrop spectrophotometer (Thermo 
Fisher) and cDNA was generated from each RNA prep using a High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). Each qPCR reaction contained 20 ng of cDNA. qPCR results were normalized to the housekeeping gene 
HTB2. All qPCR primers were designed manually using Benchling. 
 
Ligand Sensing Protocol 
All sensor strains were picked into 500 μL of synthetic complete media and grown in 2.2 mL 96 deep-well plates at 30 °C in 
an Infors HT Multitron, shaking at 700 rpm overnight. The next day, saturated strains were then diluted 1:100 into fresh 
media. After 2 h of incubation the strains were induced with their respective ligands and incubated for a further 4 h. All 
ligands were dissolved in DMSO, and the final concentration of DMSO in all cultures was 1 %. For strains using the TetR-
PRD or Z3E-PRD transcription factor, aTc and β-estradiol was added during the back dilution at time 0 h. To perform flow 
cytometry and plate reader measurements, 200 μL from each well was directly transferred to a 96-well clear, flat-bottom 
microplate (Corning). 
For monoclonal cell experiments, cell fluorescence was measured by an Attune NxT Flow Cytometer (Thermo Scientific) 
with the following settings for measuring sfGFP: FSC 300 V, SSC 350 V, BL1 500 V. Fluorescence data was collected from 
10,000 cells for each experiment and analyzed using FlowJo software. For polyclonal cell experiments, cell fluorescence 
was measured by a Synergy HT Microplate Reader (BioTek) with the following settings for measuring sfGFP: excitation 
485/20, emission 528/20, gain 80. Unnormalized, raw fluorescence readings from each well were used for data analysis. 
 
Detection of Microbially Produced Melatonin 
Samples for mass spectrometry and the MTNR1A sensor were prepared by centrifuging yeast cultures at 4000 rpm in a 
large desktop centrifuge for 10 minutes at 4 °C and extracting the supernatant. Supernatant samples were kept on ice before 
running on the LC-MS or transferred to the -20 °C for later use. No further sample preparation was performed on the 
supernatant sample before running on the LC-MS. Melatonin standards were kept in 100% DMSO before being diluted in 
spent media. Spent media was prepared from BY4741 in the same manner as the measured yeast. 
An LC-MS method was developed for the measurement of melatonin in media, using an Agilent 1290 UPLC and 6550 
quadrupole – time-of-flight (Q-ToF) mass spectrometer with electrospray ionization (Santa Clara, CA). The UPLC column 
was an Agilent Zorbax Eclipse Plus C-18, 2.1 x 50mm and 1.8um particle size. The UPLC buffers were 0.1% formic acid in 
water and 0.1% formic acid in acetonitrile (v/v). The gradient elution method is detailed below. 
The LC Gradient Elution Method for the Measurement of Melatonin in Media. 
Time (minutes) % Solvent A % Solvent B Flow rate (mL/min) 
0 100 0 0.5 
0.5 100 0 0.5 
1.5 70 30 0.5 
2 5 95 0.5 
2.5 5 95 0.5 
2.6 100 0 0.5 
3.6 100 0 0.5 
 
Quantitation was based on the LC retention time from melatonin standard solutions and the area of accurately measured 
diagnostic ions from the molecule, namely the protonated molecule, [M+H]+, along with an in-source fragment (see below). 
The solutions of a melatonin standard in media were used to generate calibration curves. 
The MS Ions Used for the Measurement of Melatonin. 
 Quantifier ion [M+H]+ Qualifier ion [M+H-C2H5NO] 
Melatonin (C13H16N2O2) 233.1285 174.0913 
 
To measure the melatonin from producer strains using the MTNR1A sensor strains, 50 μL of supernatant was added to an 
adjusted 450 μL volume of the sensor cells and run on the flow cytometer according to the ligand sensing protocol. Melatonin 
concentrations were then calculated from a standard curve. 
 
Dose-Response Fitting 
All presented dose-response fittings were generated in Prism 7 (GraphPad), which was used to determine the logEC50 and 
Hill slope. To determine all remaining properties of the dose-response curve, curve fitting was performed using Python 
(SciPy and Matplotlib) using the 4PL model (Equation 2), where x is the concentration, A is the minimum asymptote, B is 
the steepness, C is the inflection point and D is the maximum asymptote. 
(Equation 2) 
𝑓(𝑥) = 𝐴 − 𝐷1 + 5𝑥𝐶78 + 𝐷 
 
Computational Modeling 
To model biochemical reactions systems, it is customary to use a set of ordinary differential equations (ODEs) to describe 
changes in concentrations of biochemical species. The systems of equations will be defined as shown in Equation 3. 
(Equation 3) 𝑑𝑥𝑑𝑡 = 𝑓:(𝑥, 𝑦,… , 𝑡) 𝑑𝑦𝑑𝑡 = 𝑓>(𝑥, 𝑦,… , 𝑡) … 
Where in this case, 𝑥, 𝑦,… are the concentrations of molecular species within the system, and 𝑓:, 𝑓>, … are functions 
describing the molecular interactions. 
Numerical integration of the system of ODEs may allow us to derive the concentration of all molecular species at a certain 
timepoint. Simulations from numerical integration are taken out by MATLAB R2017a offered by MathWorks. 
 
GPCR Ternary Complex Model 
Rationale and Implementation 
The aim to formulate a system of ODEs of the Ste2, Gpa1, and Ste4:Ste18 promoter library required a top-down approach 
via reproduction of similar trends against general experimental results. In terms of the Ste2 library, an increase in receptor 
concentration directly increases maximum response while retaining low constitutive signaling. An increase in [Gpa1] or [Gɑ] 
in the pathway should demonstrate an optimal response, where a specific concentration of [Gɑ] produces the maximum 
response while having constitutive signaling. Increases in [Ste4:Ste18] or [Gβγ] should also demonstrate an optimal response 
with some basal activity. Thus, it is important to design a detailed system of ODEs which differentiates the ligand-induced 
responses against the constitutive response. 
Moreover, since the refactored strain observe changes in response by modifying the receptor (Ste2), Gɑ subunit (Gpa1), 
and Gβγ subunit (Ste4:Ste18) concentration, a detailed model focusing on receptor/G protein interactions was used. Although 
there are models presenting full yeast pheromone ODE models in detail (Kofahl and Klipp, 2004; Shao et al., 2006), these 
models are not be ideal for demonstrating the intricate changes in multiple constitutive activities and normal responses 
within the receptor/G protein interactions. Thus, we have chosen as our basis of the mathematical model our previously 
described cubic ternary complex model (Bridge et al., 2018), which focuses upon the receptor and heterotrimeric G protein 
complex. In contrast to our previous work, our model output is the changes in free Gβγ subunits since this is how the S. 
cerevisiae pheromone-response pathway mediates downstream signaling (Whiteway et al., 1989). Upon release of the Gβγ 
dimer from Gɑ downstream signaling continues through interaction with Ste5 and recruitment of a MAPK cascade (Ste11, 
Ste7 and Fus3 respectively). It has been reported that the MAPK-cascade does not modify the Ste2/G protein dynamics 
and simply acts to amplify and transduce the response from the plasma membrane to the nucleus (Yi et al., 2003). As such, 
given our specific interest in the dynamics of the R/G protein and the fact that our refactored yeast cells are designed to be 
linearly correlated we have not included the MAPK in our model simulations with the exception of Ste5, which is considered 
as the downstream effector. 
 
Model Formulation 
Here, we formulate the ODE model dynamics, as we have described previously (Bridge et al., 2018; Croft et al., 2013; Prokic 
et al., 2015; Smith et al., 2009) for refactored S. cerevisiae strain yWS1922 to recapitulate results obtained through varying 
expressions of Ste2 or Gpa1 through a promoter library (Figure 2D+2E, Experimental). The basis of the mathematical 
model used is from a cubic ternary complex model (Bridge et al., 2018), in which a receptor may be under its inactive 
conformation R or its active conformation R*. Furthermore, a receptor may bind to G protein G, and activation of receptor 
may cause G to dissociate and undergo the G protein cycle. The model describes ligand binding, receptor activation, G 
protein binding and the G protein cycle (Bridge et al., 2018). The scheme used for the reaction model is depicted in Figure 
S8A with detailed ODEs in Equation 4. The synthesis and degradation of the models were assumed to be slower compared 
to the signaling events and thus omitted for simplicity. Taking ligand concentration as a constant, our system consists of 8 
receptor states and 8 non-receptor bound G protein states, with a total for the system of 16 ODEs. For model outputs, 
concentrations [Gβγ*STE5] will be taken as subsequent downstream pathways are designed to be linearly correlated in the 
system. For the individual kinetic rate constants, the lowercase k was used, along with subscripts + and – to denote forward 




Here we present the numerical results used to illustrate the Ste2 and Gpa1 promoter library model. Both concentration-
response curves are created through MATLAB R2017a using the pre-installed ODE solver ode15s. ODEs were solved to 
obtain endpoint concentration of [Gβγ*] after 1000 timepoints (Figure 2D+2E, Model). Prior to the addition of ligand, the 
system was run for 1e8 timepoints to enable complex intermediates to obtain equilibrium (Bridge et al., 2018; Croft et al., 
2013; Prokic et al., 2015; Smith et al., 2009). The simulated results demonstrate similar trends to the ‘wet’ experimental data 
(Figure 2D+2E, Experimental – Ste2), where increases in Ste2 (R in the model) concentration shows an increase in 
maximum response. Conversely, for a fixed concentration of R increasing concentrations of Gpa1 (G in the model) 
demonstrates a non-monotonic relationship between G protein concentration and maximal signaling response (Figure 
2D+2E, Experimental – Gpa1). For fixed concentrations of R and Gɑ while increasing Ste4/Ste18 (Gβγ in the model), a non-
monotonic relationship shows an optimal signaling response (Figure 2D+2E, Experimental –Ste4:Ste18).  The base 
parameter set, including initial species concentrations used for both simulations can be found below. Parameter values were 
qualitatively fit through experimental dose-response results of the Gpa1 and Ste2 promoter library, retaining source values 
when possible. 
Parameter Values Used for Constructing the Computational Gpa1 and Ste2 Promoter library. 
Parameter Meaning Values Units Source 
kL+ Ligand binding rate  4E+7 M-1s-1 Fitted 
kL- Ligand unbinding rate 3.10E-01 s-1 (Bridge et al., 2010) 
kact+ Receptor activation rate to R* 1.00E+00 s-1 “ 
kact- Receptor deactivation rate from R* 1.00E+03 s-1 “ 
kG+ G protein binding rate 1.00E+08 M-1s-1 “ 
kG- G protein unbinding rate 1.00E-01 s-1 “ 
kGRA+ G protein re-association rate 7.00E+08 M-1s-1 Fitted 
kGRA- G protein dissociation rate 1.30E-03 s-1 (Bridge et al., 2010) 
khyd+ Hydrolysis rate of GαGTP 1.00E-04 s-1 “ 
khyd- Exchange rate of GTP to GDP at Gα 1.00E-04 s-1 “ 
kGTP+ R*G dissociation rate  1.00E-02 s-1 Fitted 
𝑑[𝑅]𝑑𝑡 = 𝑘CD[𝐿𝑅] −	𝑘CG[𝐿][𝑅] +	𝑘HIJD[𝑅∗] −	𝑘HIJG[𝑅] +	𝑘LD[𝑅𝐺] −	𝑘LG[𝑅][𝐺] 𝑑[𝐿𝑅]𝑑𝑡 = 	𝑘CG[𝐿][𝑅] −	𝑘CD[𝐿𝑅] +	𝜁D𝑘HIJD[𝐿𝑅∗] −	𝜁G𝑘HIJG[𝐿𝑅] +	𝜈D𝑘LD[𝐿𝑅𝐺] −	𝜈G𝑘LG[𝐿𝑅][𝐺] 𝑑[𝑅∗]𝑑𝑡 = 	𝑘HIJG[𝑅] −	𝑘HIJD[𝑅∗] +	𝜁D𝑘CD[𝐿𝑅∗] −	𝜁G𝑘CG[𝐿][𝑅∗] +	𝜇D𝑘LD[𝑅∗𝐺] −	𝜇G𝑘LG[𝑅∗] +	𝑘LQRG[𝑅∗𝐺] 𝑑[𝐿𝑅∗]𝑑𝑡 = 	 𝜁G𝑘HIJG[𝐿𝑅] −	𝜁D𝑘HIJD[𝐿𝑅∗] −		𝜁D𝑘CD[𝐿][𝑅∗] −	𝜁D𝑘CD[𝐿𝑅∗] +	𝜇D𝜈D𝑘LD[𝐿𝑅∗] −	𝜇G𝜈G𝑘LG[𝐿𝑅∗][𝐺] +	𝜈D𝑘LQRG[𝐿𝑅∗𝐺] 𝑑[𝑅𝐺]𝑑𝑡 = 	𝑘LG[𝑅][𝐺] −	𝑘LD[𝑅𝐺] +	𝜈D𝑘CD[𝐿𝑅𝐺] −	𝜈G𝑘CG[𝐿][𝑅𝐺] +	𝜇D𝑘HIJD[𝑅∗𝐺] −	𝜇G𝑘HIJG[𝑅𝐺] 𝑑[𝐿𝑅𝐺]𝑑𝑡 = 	 𝜈G𝑘LG[𝐿𝑅][𝐺] −	𝜈D𝑘CD[𝐿𝑅𝐺] +	𝜈G𝑘CG[𝐿][𝑅𝐺] −	𝜈D𝑘CD[𝐿𝑅𝐺] +	𝜇D𝜁D𝑘HIJD[𝐿𝑅∗𝐺] −	𝜇G𝜁G𝑘HIJG[𝐿𝑅𝐺] 𝑑[𝑅∗𝐺]𝑑𝑡 = 	𝜇G𝑘LG[𝑅∗][𝐺] −	𝜇D𝑘LD[𝑅∗𝐺] +	𝜇G𝑘HIJG[𝑅𝐺] −	𝜇D𝑘HIJD[𝑅∗𝐺] −	𝑘LQRG[𝑅∗𝐺] 𝑑[𝐿𝑅∗𝐺]𝑑𝑡 = 	𝜇G𝜈G𝑘LG[𝐿𝑅∗][𝐺] −	𝜇D𝜈D𝑘LD[𝐿𝑅∗] +	𝜁G𝜈G𝑘CG[𝐿][𝑅∗𝐺] −	𝜁D𝜈D𝑘CD[𝐿𝑅∗𝐺] +	𝜇G𝜁G𝑘HIJG[𝐿𝑅𝐺] −	𝜇D𝜁D𝑘HIJD[𝐿𝑅∗𝐺] −	𝜈D𝑘LQRG[𝐿𝑅∗𝐺] 𝑑[𝐺]𝑑𝑡 = 	𝑘LD[𝑅𝐺] −	𝑘LG[𝑅][𝐺] +	𝜈D𝑘CD[𝐿𝑅𝐺]	−	𝜈G𝑘LG[𝐿𝑅][𝐺] + 𝑘LSTG[𝛼LVR][𝛽𝛾] +	𝑘LSTG[𝛼LVR][𝛽𝛾∗] −	𝑘LSTD[𝐺] +	𝜇D𝑘LD[𝑅∗𝐺] −	𝜇G𝑘LG[𝑅∗][𝐺]+	𝜇D𝜈D𝑘LD[𝐿𝑅∗] 	− 	𝜇G𝜈G𝑘LG[𝐿𝑅∗][𝐺] 𝑑[𝛼LVR]𝑑𝑡 = 	𝑘Y>ZG[𝛼LQR] −	𝑘Y>ZD[𝛼LVR] +	𝑘LSTD[𝐺] −	𝑘LSTG[𝛼LVR][𝛽𝛾] −	𝑘LSTG[𝛼LVR][𝛽𝛾∗] 𝑑[𝛼LQR]𝑑𝑡 = 	𝑘Y>ZD[𝛼LVR]	−	𝑘Y>ZG[𝛼LQR] +	𝑘LQRG[𝑅∗𝐺] +	𝜈D𝑘LQRG[𝐿𝑅∗𝐺] 𝑑[𝛽𝛾]𝑑𝑡 = 	−	𝑘LSTG[𝛼LVR] −	𝑘I[\HIJ[𝛽𝛾] + 𝑘]^_[𝛽𝛾∗] − 𝑘`Ga[𝑆𝑇𝐸5][𝛽𝛾∗] + 𝑘`fa[𝛽𝛾∗𝑆𝑇𝐸5] 𝑑[𝛽𝛾∗]𝑑𝑡 = 	𝑘LSTD[𝐺] +	𝑘LQRG[𝑅∗𝐺] +	𝜈D𝑘LQRG[𝐿𝑅∗𝐺] +	𝑘I[\HIJ[𝛽𝛾] − 𝑘]^_[𝛽𝛾∗] −	𝑘LSTG[𝛼LVR][𝛽𝛾∗] − 𝑘`Gg[𝑆𝑇𝐸5][𝛽𝛾∗] + 𝑘`fg[𝛽𝛾∗𝑆𝑇𝐸5] 𝑑[𝑆𝑇𝐸5]𝑑𝑡 = 𝑘`Dg[𝛽𝛾∗𝑆𝑇𝐸5] − 𝑘`Gg[𝑆𝑇𝐸5][𝛽𝛾∗] − 𝑘`Ga[𝑆𝑇𝐸5][𝛽𝛾] + 𝑘`Da[𝛽𝛾𝑆𝑇𝐸5] 𝑑[𝛽𝛾∗𝑆𝑇𝐸5]𝑑𝑡 = 𝑘`Gg[𝑆𝑇𝐸5][𝛽𝛾∗] − 𝑘`Da[𝛽𝛾𝑆𝑇𝐸5] 𝑑[𝛽𝛾𝑆𝑇𝐸5]𝑑𝑡 = 𝑘`Ga[𝑆𝑇𝐸5][𝛽𝛾] − 𝑘`fa[𝛽𝛾𝑆𝑇𝐸5] 
ν+ Forward cooperativity factor for ligand binding a G bound receptor  1.00E+00   
(Bridge et al., 
2010) 
ν- Backward cooperativity factor for ligand binding  1.00E+00   “ 
ζ+ Forward cooperativity factor for ligand-bound R activation 1.00E+03   “ 
ζ- Backward cooperativity factor for ligand bound R activation 1.00E+00   “ 
μ+ Forward cooperativity factor for G bound R activation 1.00E+00   “ 
μ- Backward cooperativity factor for G bound R activation 1.00E+00   “ 
kconact Constitutive activity of Gβɣ       1.00E-10 s-1 Fitted 
krev Reverse reaction of constitutive activity in Gβɣ       1.00E-10 s-1 “ 
kE+1 STE5 binding rate to Gβɣ*       1.00E+3 M-1s-1 “ 
kE+2 STE5 binding rate to Gβɣ       1.00E+9 M-1s-1 “ 
kE-1 STE5 dissociation rate to Gβɣ*       1.00E+0 s-1 “ 
kE-2 STE5 dissociation rate to Gβɣ 1.00E+0 s-1 “ 
Rtot Total receptor concentration 4.15E-10 M “ 
Gtot Total G protein concentration 4.15E-10 M “ 
Ltot Total ligand concentration 1.00E-04 M “ 
 
Since the model allows G to dissociate in the absence of Ligand L or R* interaction, multiple levels of constitutive activity 
(elevated signaling in the absence of ligand) can be made possible. Along with the main pathway of G activation through 
LR* Gɑβγ, R*Gɑβγ may also activate the G protein cycle in the absence of ligand. Gɑβγ can also dissociate and activate 
independently of R through rate constant kGRA-. To further reproduce constitutive features of the yeast pheromone cycle, 
inactive Gβγ may also be activated to be Gβγ* through kconact, which is a simplification of Gβγ interacting with downstream 
effectors. This detailed description of the constitutively active pathways allowed us to recapitulate the low constitutive 
signaling in the experimental results.  To demonstrate how signaling decreases from an optimal point when increasing Gβγ, 
it has been anticipated that at very high concentrations, Gβγ is unable to be trafficked to the plasma membrane due to the 
lack of Gɑ, but still affecting the pathway by binding to downstream effectors prematurely (Pryciak and Huntress, 1998; Song 
et al., 1996). This has been described simply in the model by showing how Gβγ and Gβγ* compete for the same effector 
(Ste5). At low initial concentrations of Gβγ, little is available to bind to Ste5 so only the Gβγ that has been activated by 
interaction with the Ste2/Gpa1 complex (Gβγ*) will actively bind to Ste5 (due to its higher affinity). However, when the initial 
concentrations of Gβγ are increased free Gβγ is able to compete with the Gβγ* and so sequesters the Ste5 species into an 
inactive complex so reducing the overall signaling maxima. 
 
Ste2/Gpa1 Feedback Model 
Rationale and Implementation 
It has been well documented (Kofahl and Klipp, 2004; Shao et al., 2006) that the intracellular concentrations both Ste2 and 
Gpa1 increase upon pheromone stimulation. This arises due to positive feedback (at the transcriptional level – Ste12) 
thereby increasing the amount of available Ste2/Gpa1 present at the shmooing tip (Shao et al., 2006). Since expression of 
all components in our refactored yeast cells are driven through constitutive promoters, not pheromone-inducible ones, we 
wondered what impact positive feedback would have upon the response output. We therefore constructed a model derived 
from the Ste2/Gpa1 model described previously (see Figure S8A) but incorporating reaction rates to enable the 
concentration of either/both Ste2/Gpa1 to increase upon production of free Gβγ dimer (our model output). We hypothesized 
that increasing both Ste2 and Gpa1 concentrations (R and G respectively in the mode) through a positive feedback loop 
would enable enhanced maximal signaling (increased EMax) production while retaining a low basal activity through 
suppression by Gpa1 (Note Gpa1 acts to sequester free Gβγ so blocking signaling (Whiteway et al., 1989)). 
 
Model Formulation 
The formulation of the system of ODEs for the feedback model requires additional components to the previous system. 
Since the feedback loop is likely to involve multiple transcription/translation processes, our model required extension from 
the single ternary complex model to involve the whole refactored pheromone signaling pathway. In addition, long-term 
changes in the signaling components must also be considered. To retain a simplified model but that reflected dynamics at 
the Ste2/Gpa1 level but accounted for the MAPK cascade and gene expression we introduced two arbitrary molecular 
species (downstream of our readout free Gβγ): X1 and X2. Both can either be in an inactive or active state (denoted X or X* 
respectively). Once X2 is in its active state it acts as a promoter, directly increasing concentrations of Ste2, Gpa1, or both. 
The basic scheme of the system of ODEs is denoted in Figure S8B.  
The detailed system of ODEs can be found in Equation 5.  In addition to the feedback loop, synthesis and degradation rates 
have also been considered in the parameter rates due to the longer timescale of the system. This relatively detailed system 
of ODEs consists of 8 receptor states, 5 non-receptor bound G protein states, and 4 downstream signaling states totaling 




Here we present the numerical results to illustrate the Ste2 and Gpa1 feedback model. Final parameter values can be found 
below. ODE results shown are endpoint concentration of [Gβγ] after 1000 timepoints, with a 1e8 timepoint equilibration 
(Bridge et al., 2018; Croft et al., 2013; Smith et al., 2009). The simulated results seem to show similar trends against the 
experimental data, with an increase in maximum while retaining a low basal activity to the system (Figure S4F+S4G). 
Parameter Values Used to Demonstrate the Yeast Feedback. 
Parameter Meaning Values Units 
kL+ Ligand binding rate  9.40E+04 M-1s-1 
kL- Ligand unbinding rate 3.10E-01 s-1 
kact+ Receptor activation rate to R* 1.00E+00 s-1 
kact- Receptor deactivation rate from R* 1.00E+03 s-1 
kG+ G protein binding rate 1.00E+08 M-1s-1 
kG- G protein unbinding rate 1.00E-01 s-1 
kGRA+ G protein re-association rate 7.00E+08 M-1s-1 
kGRA- G protein dissociation rate 1.30E-03 s-1 
khyd+ Hydrolysis rate of GαGTP 1.00E-01 s-1 
khyd- Exchange rate of GTP to GDP at Gα 1.00E-04 s-1 
kGTP+ R*G dissociation rate  1.00E+00 s-1 
kRGS RGS activity rate to hydrolyze GɑGTP 4.00E+05 s-1 
𝑑[𝑅]𝑑𝑡 = 𝑘CD[𝐿𝑅] −	𝑘CG[𝐿][𝑅] +	𝑘HIJD[𝑅∗] −	𝑘HIJG[𝑅] +	𝑘LD[𝑅𝐺] −	𝑘LG[𝑅][𝐺] + 𝑘Sh>\ − 𝑘Si\J[𝑅] + 𝑘LZ^j([𝑅𝐺] 	+ 	𝑅∗𝐺) + 𝑘SkZlm[𝑋2∗] 𝑑[𝐿𝑅]𝑑𝑡 = 	𝑘CG[𝐿][𝑅] −	𝑘CD[𝐿𝑅] +	𝜁D𝑘HIJD[𝐿𝑅∗] −	𝜁G𝑘HIJG[𝐿𝑅] +	𝜈D𝑘LD[𝐿𝑅𝐺] −	𝜈G𝑘LG[𝐿𝑅][𝐺] − 𝑘Si\J[𝐿𝑅] + 𝑘LZ^j[𝐿𝑅𝐺] 𝑑[𝑅∗]𝑑𝑡 = 	𝑘HIJG[𝑅] −	𝑘HIJD[𝑅∗] +	𝜁D𝑘CD[𝐿][𝑅∗] −	𝜁G𝑘CG[𝐿][𝑅∗] +	𝜇D𝑘LD[𝑅∗𝐺] −	𝜇G𝑘LG[𝑅∗] +	𝑘LQRG[𝑅∗𝐺] − 𝑘Si\J[𝑅∗] 𝑑[𝐿𝑅∗]𝑑𝑡 = 	 𝜁G𝑘HIJG[𝐿𝑅] −	𝜁D𝑘HIJD[𝐿𝑅∗] −		𝜁D𝑘CD[𝐿][𝑅∗] −	𝜁D𝑘CD[𝐿𝑅∗] +	𝜇D𝜈D𝑘LD[𝐿𝑅∗] −	𝜇G𝜈G𝑘LG[𝐿𝑅∗][𝐺] +	𝜈D𝑘LQRG[𝐿𝑅∗𝐺] − 𝑘Si\J[𝐿𝑅∗] + 𝑘LZ^j[𝐿𝑅∗𝐺] 𝑑[𝑅𝐺]𝑑𝑡 = 	𝑘LG[𝑅][𝐺] −	𝑘LD[𝑅𝐺] +	𝜈D𝑘CD[𝐿𝑅𝐺] −	𝜈G𝑘CG[𝐿][𝑅𝐺] +	𝜇D𝑘HIJD[𝑅∗𝐺] −	𝜇G𝑘HIJG[𝑅𝐺] − 𝑘Si\J[𝑅𝐺] − 𝑘LZ^j[𝑅𝐺] 𝑑[𝐿𝑅𝐺]𝑑𝑡 = 	 𝜈G𝑘LG[𝐿𝑅][𝐺] −	𝜈D𝑘CD[𝐿𝑅𝐺] +	𝜈G𝑘CG[𝐿][𝑅𝐺] −	𝜈D𝑘CD[𝐿𝑅𝐺] +	𝜇D𝜁D𝑘HIJD[𝐿𝑅∗𝐺] −	𝜇G𝜁G𝑘HIJG[𝐿𝑅𝐺] − 𝑘Si\J[𝐿𝑅𝐺] − 𝑘LZ^j[𝐿𝑅𝐺] 𝑑[𝑅∗𝐺]𝑑𝑡 = 	𝜇G𝑘LG[𝑅∗][𝐺] −	𝜇D𝑘LD[𝑅∗𝐺] +	𝜇G𝑘HIJG[𝑅𝐺] −	𝜇D𝑘HIJD[𝑅∗𝐺] −	𝑘LQRG[𝑅∗𝐺] − 	𝑘_𝑅𝑖𝑛𝑡	[𝑅∗𝐺] − 	𝑘_𝐺𝑑𝑒𝑔	[𝑅∗𝐺] 𝑑[𝐿𝑅∗𝐺]𝑑𝑡 = 	𝜇G𝜈G𝑘LG[𝐿𝑅∗][𝐺] −	𝜇D𝜈D𝑘LD[𝐿𝑅∗] +	𝜁G𝜈G𝑘CG[𝐿][𝑅∗𝐺] −	𝜁D𝜈D𝑘CD[𝐿𝑅∗𝐺] +	𝜇G𝜁G𝑘HIJG[𝐿𝑅𝐺] −	𝜇D𝜁D𝑘HIJD[𝐿𝑅∗𝐺] −	𝜈D𝑘LQRG[𝐿𝑅∗𝐺]− 𝑘Si\J[𝐿𝑅∗𝐺] − 𝑘LZ^j[𝐿𝑅∗𝐺] 𝑑[𝐺]𝑑𝑡 = 	𝑘LD[𝑅𝐺] −	𝑘LG[𝑅][𝐺] +	𝜈D𝑘CD[𝐿𝑅𝐺]	−	𝜈G𝑘LG[𝐿𝑅][𝐺] + 𝑘LSTG[𝛼LVR][𝛽𝛾] +	𝑘LSTG[𝛼LVR][𝛽𝛾∗] −	𝑘LSTD[𝐺] +	𝜇D𝑘LD[𝑅∗𝐺] −	𝜇G𝑘LG[𝑅∗][𝐺]+	𝜇D𝜈D𝑘LD[𝐿𝑅∗] 	− 	𝜇G𝜈G𝑘LG[𝐿𝑅∗][𝐺] + 𝑘Lh>\ −	𝑘LZ^j[𝐺] +	𝑘Si\J([𝑅𝐺] 	+ [𝑅∗𝐺] + [𝐿𝑅𝐺] + [𝐿𝑅∗𝐺]) +	𝑘LkZlm[𝑋2∗] 𝑑[𝛼LVR]𝑑𝑡 = 	𝑘Y>ZG[𝛼LQR] −	𝑘Y>ZD[𝛼LVR] +	𝑘LSTD[𝐺] −	𝑘LSTG[𝛼LVR][𝛽𝛾] + 𝑘tLVRkZlm[𝑋2∗] − 𝑘LZ^j[𝛼LVR] 𝑑[𝛼LQR]𝑑𝑡 = 	𝑘Y>ZD[𝛼LVR]	−	𝑘Y>ZG[𝛼LQR] +	𝑘LQRG[𝑅∗𝐺] +	𝜈D𝑘LQRG[𝐿𝑅∗𝐺] + 𝑘tLQRkZlm[𝑋2∗] − 𝑘LZ^j[𝛼LQR] 𝑑[𝛽𝛾]𝑑𝑡 = 	𝑘LSTD[𝐺] +	𝑘LQRG[𝑅∗𝐺] +	𝜈D𝑘LQRG[𝐿𝑅∗𝐺] −	𝑘LSTG[𝛼LVR][𝛽𝛾] + 𝑘uvkZlm[𝑋2∗] − 𝑘LZ^j[𝛽𝛾] 𝑑[𝑋1]𝑑𝑡 = 𝑘:gD[𝑋1∗] − 𝑘wgG[𝛽𝛾][𝑋1] 𝑑[𝑋2]𝑑𝑡 = 𝑘:aD[𝑋2∗] − 𝑘waG[𝑋1∗][𝑋2] 𝑑[𝑋1∗]𝑑𝑡 = 𝑘wgG[𝛽𝛾][𝑋1] −	𝑘:gD[𝑋1∗] 𝑑[𝑋2∗]𝑑𝑡 = 𝑘waG[𝛽𝛾][𝑋2] −	𝑘:aD[𝑋2∗] 
 
kX1+ X1 activation rate to X1* 2.00E-03 s-1 
kX1- X1* inactivation rate to X1 2.00E-04 s-1 
kX2+ X2 activation rate to X2* 2.00E-03 s-1 
kX2- X2* inactivation rate to X2 2.00E-04 s-1 
kRsyn Receptor synthesis rate 1.20E-14 s-1 
kRint Receptor internalization rate 2.90E-04 s-1 
kRGSsyn RGS synthesis rate 3.30E-11 s-1 
kRGSdeg RGS degradation rate 3.00E-04 s-1 
kGsyn G protein synthesis rate 9.55E-14 s-1 
kGdeg G protein degradation rate  2.30E-04 s-1 
ν+ Forward cooperativity factor for ligand binding a G bound receptor  1.00E+00   
ν- Backward cooperativity factor for ligand binding  1.00E+00   
ζ+ Forward cooperativity factor for ligand-bound R activation 1.00E+03   
ζ- Backward cooperativity factor for ligand bound R activation 1.00E+00   
μ+ Forward cooperativity factor for G-bound R activation 1.00E+00   
μ- Backward cooperativity factor for G bound R activation 1.00E+00   
Rtot Total receptor concentration 4.15E-10 M 
Ltot Total ligand concentration 1.00E-04 M 
X1init Total X1 concentration 1.00E-07 M 
X2init Total X2 concentration 1.00E-07 M 
 
Digital Sensor Model 
Rationale and Implementation 
An application demonstrating the flexibility in the operational range of the yeast GPCR-based sensors was to use mixed 
populations of communicating strains to narrow the range, creating concentration-response curves close to a digital, ‘all or 
none’ response. The aim of this digital sensor model was to describe, in detail, the interactions between yeast cells in which 
their properties are modified so the product of one cell (ɑ-factor; Amplifier cell) becomes the agonist of another (Reporter 
cell). The Reporter cell expresses, under the constitutive RPL18B promoter, Bar1, a protease which degrades ɑ-factor 
(Sprague and Herskowitz, 1981). It has been suggested that the presence of Bar1 reduces ‘non-productive mating’ events 
in S. cerevisiae by rapidly degrading low levels of ɑ-factor (Segota and Franck, 2017). In essence, Bar1 works as a barrier 
between the ɑ-factor producing cell and the reporter cell, degrading the low levels of constitutively released ɑ-factor from 
the Amplifier cell. As concentrations of stimulating agonist (melatonin) increase, the proteolytic activity of Bar1 is saturated 
with increased ɑ-factor, allowing the activation of the reporter strain.  
 
Model Formulation 
Our previous modelling efforts have concentrated upon the dynamics of the R/Gɑβγ complex. However, to enable qualitative 
modelling of the digital sensor (effectively two entire pheromone signaling cascades) we decided to use a heavily reduced 
model for the R/Gɑβγ complex. We felt this important since our focus is on the interactions/behaviors of the two cells rather 
than solely the G protein cycle within a cell. Thus, we have chosen a reduced model which accurately describes overall in 
vivo responses for time- and dose-dependent effects in the system. 
To deviate from processes within the cell and focus on the interactions between cells, a reduced yeast pheromone pathway 
based on a model developed by Smith et al. (2009) was used. The structure of the reduced model consisting of 9 ODEs for 
each cell, modified to fit the experimental system through the addition of Bar1 interaction with ɑ-factor, along with a 
modification to set a maximum amount of possible product each cell can produce.  
The overall scheme used for the model is shown in Figure S8C. In this system, receptor states are simplified to two (R and 
R*) and G protein states are simplified to three species (Goff, Gon, and GonEffector). The activated G protein will interact with 
an Effector protein (Ste5) which consequently activates a series of delay species to simulate the MAPK-like signaling 
cascade. prez3 is a term responsible for creating the final product of each cell by being directly converted to its corresponding 
product. It will act as a ‘cap’ by limiting maximum production within the concentration of prez3. Constitutive activity of each 
of the cell is achieved by directly adding GFP (the product generated from the reporter cell) to the system.  
The detailed system of ODEs can be found in Equation 6. Synthesis and degradation of the system are omitted for simplicity, 
apart from R* internalization. Our system includes the full pheromone response of two yeast cells, interactions between the 
two cells, and the constitutive protease activity of Bar1 consisting of 23 ODEs. Model outputs are either the product of the 




260-minute endpoint readings of the refactored melatonin-sensitive yeast cell (MTNR1A sensor), Digital Feedback including 
the reporter cell without constitutive Bar1 activity, and Digital Feedback with Bar1 activity data were fitted simultaneously. 
Since most of the yeast pheromone system except the core MAPK cascade were refactored within the system, parameter 
values related to the receptor and its subsequent G protein activation rates were fitted using COPASI 4.16 (Hoops et al., 
2006). Moreover, parameters and species introduced in the system for the first time were fitted against experimental data 
mentioned above. The set of finalized parameter values were obtained through parameter estimation algorithms provided 
in COPASI. To simulate and accurately fit incubation times in COPASI, constitutive fluorescence has been set as the initial 
concentrations of the corresponding products (3.1 nM for MTNR1A sensor, 10.4 nM for digital feedback without Bar1, and 
4.4 nM for digital feedback with Bar1). Two optimization algorithms were tested: the Hooke and Jeeves algorithm and the 
evolutionary programming algorithm. Both methods reliably converged to the same minimum within the parameter space, 
which were thus considered as a global minimum. 
 
𝑑[𝑅g]𝑑𝑡 = [𝑅g∗]𝑘xg − [𝐿][𝑅g]𝑘gg − [𝑅g]𝑘I[\g 𝑑[𝑅g∗]𝑑𝑡 = [𝐿][𝑅g]𝑘gg − [𝑅g∗]𝑘xg − [𝑅g∗]𝑘yg + [𝑅g]𝑘I[\g 𝑑[𝐺[kkg]𝑑𝑡 = [𝐺[\g]𝑘zg − [𝑅g∗]{𝐺[kkg|𝑘ag 𝑑[𝐺[\g]𝑑𝑡 = [𝑅g∗]{𝐺[kkg|𝑘ag + [𝐺[\g𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟g]𝑘g − [𝐺[\g]𝑘zg − [𝐺[\g][𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟g]𝑘g 𝑑[𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟g]𝑑𝑡 = [𝐺[\g𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟g]𝑘g − [𝐺[\g][𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟g]𝑘g 𝑑[𝐺[\g𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟g]𝑑𝑡 = [𝐺[\g][𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟g]𝑘g − [𝐺[\g𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟g]𝑘g 𝑑[𝑧gg]𝑑𝑡 = [𝐺[\g𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟g]𝛼g − [𝑧gg]𝛽g 𝑑[𝑧ag]𝑑𝑡 = [𝑧gg][𝛼gg] − [𝑧ag]𝛽gg 𝑑[𝑝𝑟𝑒𝛼𝑓𝑎𝑐𝑡𝑜𝑟]𝑑𝑡 = [𝛼𝑓𝑎𝑐𝑡𝑜𝑟]𝛽ag − [𝑧ag][𝑝𝑟𝑒𝛼𝑓𝑎𝑐𝑡𝑜𝑟]𝛼ag 𝑑[𝛼𝑓𝑎𝑐𝑡𝑜𝑟]𝑑𝑡 = [𝑧ag][𝑝𝑟𝑒𝛼𝑓𝑎𝑐𝑡𝑜𝑟]𝛼ag − [𝛼𝑓𝑎𝑐𝑡𝑜𝑟]𝛽ag − [𝛼𝑓𝑎𝑐𝑡𝑜𝑟][𝑅a]𝑘ga + [𝑅a∗]𝑘xa − [𝐵𝑎𝑟1][𝛼𝑓𝑎𝑐𝑡𝑜𝑟]𝑘 𝑑[𝑅a]𝑑𝑡 = [𝑅a∗]𝑘xa − [𝛼𝑓𝑎𝑐𝑡𝑜𝑟][𝑅a]𝑘ga − [𝑅a]𝑘I[\a 𝑑[𝑅a∗]𝑑𝑡 = [𝛼𝑓𝑎𝑐𝑡𝑜𝑟][𝑅a]𝑘ga − [𝑅a∗]𝑘xa − [𝑅a∗]𝑘ya + [𝑅a]𝑘I[\a 𝑑[𝐺[kka]𝑑𝑡 = [𝐺[\a]𝑘za − [𝑅a∗]{𝐺[kka|𝑘aa 𝑑[𝐺[\a]𝑑𝑡 = [𝑅a∗]{𝐺[kka|𝑘aa − [𝐺[\a𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟a]𝑘a − [𝐺[\a]𝑘za − [𝐺[\a][𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟a]𝑘a 𝑑[𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟a]𝑑𝑡 = [𝐺[\a𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟g]𝑘a − [𝐺[\a][𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟a]𝑘a 𝑑[𝐺[\a𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟a]𝑑𝑡 = [𝐺[\a][𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟a]𝑘a − [𝐺[\a𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟a] 𝑑[𝑧ga]𝑑𝑡 = [𝐺[\a𝐸𝑓𝑓𝑒𝑐𝑡𝑜𝑟a]𝛼a − [𝑧ga]𝛽a 𝑑[𝑧aa]𝑑𝑡 = [𝑧ga][𝛼ga] − [𝑧aa]𝛽ga 𝑑[𝑝𝑟𝑒𝐺𝐹𝑃]𝑑𝑡 = [𝐺𝐹𝑃]𝛽aa − [𝑧aa][𝑝𝑟𝑒𝐺𝐹𝑃]𝛼aa 𝑑[𝐺𝐹𝑃]𝑑𝑡 = [𝑧aa][𝑝𝑟𝑒𝐺𝐹𝑃]𝛼aa − [𝐺𝐹𝑃]𝛽aa 𝑑[𝐿]𝑑𝑡 = [𝑅g∗]𝑘xg − [𝐿][𝑅g]𝑘gg 𝑑[𝐵𝑎𝑟1]𝑑𝑡 = [𝐼𝑛𝑎𝑐𝑡𝑖𝑣𝑒𝐵𝑎𝑟1]𝑘 + [𝐼𝑛𝑎𝑐𝑡𝑖𝑣𝑒𝐵𝑎𝑟1]𝑘g − [𝐵𝑎𝑟1][𝛼𝑓𝑎𝑐𝑡𝑜𝑟]𝑘 𝑑[𝐼𝑛𝑎𝑐𝑡𝑖𝑣𝑒𝐵𝑎𝑟1]𝑑𝑡 = [𝐵𝑎𝑟1][𝛼𝑓𝑎𝑐𝑡𝑜𝑟]𝑘 − [𝐼𝑛𝑎𝑐𝑡𝑖𝑣𝑒𝐵𝑎𝑟1]𝑘 − [𝐼𝑛𝑎𝑐𝑡𝑖𝑣𝑒𝐵𝑎𝑟1]𝑘g 
 
Simulation Results 
Here we present the parameter values and fitted graphs of the model, which can be found below. Ligand and Receptor 
specific parameters were refitted to the experimental time course data, as well as Bar1 interaction and initial concentration. 
Initial concentrations of Receptor, Goff, and Effector were set consistently at 16 µM for both cells. 
Parameter Values Used for the Double Cell System. 
Parameter Meaning Values Units Source 
k11 Ligand binding rate 2.75E8 M
-1s-1 Fitted 
k12 1.40E5 M-1s-1 “ 
k21 Receptor activation rate to R* 2726.24 s
-1 (Smith et al., 2009) 
k22 1.21E4 s-1 “ 
k31 G protein unbinding rate 4.00E-3 s
-1 “ 
k32 4.00E-3 s-1 “ 
k41 R* internalization rate 1.06E-7 s
-1 Fitted 
k42 3.08E-8 s-1 “ 
k51 Effector binding rate 1.04E6 M
-1s-1 (Smith et al., 2009) 
k52 1.04E6 M-1s-1 “ 
k61 Effector unbinding rate 0.0942 s
-1 “ 
k62 0.0942 s-1 “ 
k71 Ligand unbinding rate 86.98 s
-1 Fitted 
k72 2.14E-7 s-1 “ 𝛼1 
Transcriptional delay 
17.75   (Smith et al., 2009) 𝛼2 17.75   “ 
β1 1859.57   “ 
β2 1859.57   “ 𝛼11 42.41   “ 𝛼12 42.41   “ 
β11 0.93   “ 
β12 0.93   “ 𝛼21 prez3 activation rate 2.80E6 s-1 Fitted 𝛼22 6.63E9 s-1 “ 
β21 prez3 inactivation rate 
6.32E-7 s-1 “ 
β22 4.90E-8 s-1 “ 
k8 ɑ-factor inactivation rate 4.19E8 M-1s-1 “ 
k9 Bar1 recycle rate 4.35E-6 s-1 “ 
k10 Bar1/ɑ-factor degradation rate 3.38E4 s-1 “ 
pre𝛼-factortot Total preɑ-factor concentration 4.66E-8 M “ 
preGFPtot Total preGFP concentration 1.52E-8 M “ 
Bar1tot Total Bar1 concentration 1.68E-10 M “ 
 
Final figures and fitting results created through the model are shown in Figure S8D. Fitting results demonstrate a lower 
EMax, higher Hill slope and increased potency upon introduction of Bar1, which was also observed in the ‘wet’ experimental 
data (Figure S7D-S7H). To provide an estimate of quality of the fitting of the model to the biological data we used residual 
analysis (Figure S8E), by which each residual is taken from the deviation of an observed value against the predicted value 
(Motulsky and Christopoulos, 2005). Residual values are defined in Equation 7. 
(Equation 7) 𝑒i	 = 	𝑦i 	− 	𝑓i 
Where a dataset has n values marked y1,…,yn (collectively defined as yi), the predicted values marked f1,…fn (collectively 
fi). All residual plots suggest an unbiased distribution with an equal deviation from 0. The residual plot digital feedback 
without Bar1 suggest a good fitting result with an unbiased distribution and a consistent variance throughout. Although 
heteroscedasticity may be observed in MTNR1A sensor and the digital feedback with Bar1, differences in variation within 
each ligand concentration suggests the natural tendency for variation to occur under the system with higher ligand 
concentration. Nevertheless, the residual plots suggest an unbiased distribution of experimental results. R2 values also 
suggest and give some information about the goodness of fit, defined in Equation 8. 
(Equation 8) 
𝑅a = 1 − ∑ 𝑒iai∑ (𝑦i − 𝑦)ai  
With ȳ as the mean of the dataset. Along with a R2 value of 97.93%, 99.90%, and 99.68% for the MTNR1A sensor, the 
digital feedback without Bar1, and digital feedback with Bar1 respectively, the non-linear regression suggests a good fit with 
the experimental data. 
Using the model, we simulate the effects of increasing concentrations of Bar1 (Figure S7C). At low concentrations of Bar1 
constitutive signaling is decreased while obtaining similar or slightly lower concentrations close to the EMax. These biological 
responses suggest that the reporter cell has a ‘capped’ response where from a defined concentration, the reporter cell will 
not exceed its maximum capacity to produce GFP. This interpretation enables the reporter cell to experience ɑfactor 
saturation and even with a relatively small concentration of Bar1 it will not be able to degrade ɑfactor sufficiently at higher 
[L] (Figure S7D). With the introduction of Bar1, basal activity can be reduced while retaining the maximum possible response 
of the system.  
 
Generation of Ultrasensitivity 
Ultrasensitivity, or the ability to create a digitalized response from a graduated input within a steady state response, is a 
well-studied field in systems biology (Zhang et al., 2013) and is said to be possible through various motifs such as multistep, 
feed-forward cooperativity, zero-order, and inhibitor ultrasensitivity. Within this ODE model, it has been designed to have 
two different mechanisms of ultrasensivity: through the amplification of the reporter cell and inhibition through Bar1. The 
MAPK cascade is a well known pathway where ultrasensitivity can arise from multistep-phosphorylation, positive feedback, 
and the cooperativity obtained through scaffolding protein, which is referred to as Ste5 in yeast (Ferrel, 1996; Shao et al., 
2006; Zhang et al., 2013). Bar1 interaction is also considered as a source of ultrasensitivity, where a competitive inhibitor 
will essentially compete against the Ste2 receptor. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Statistical tests of all experiments was performed using GraphPad Prism version 7 or MathWorks MATLAB version R2017a 
and are detailed within the legend of each figure. For flow cytometry experiments, fluorescence data was collected from 
10,000 cells for each datapoint and analyzed using FlowJo software, representing the average fluorescence of the 
population as the geometric mean. In all figures, the data points represent the mean ± SD. Curves fitted to all dose-response 
data was fitted in Prism 7 using the  Nonlinear Regression: Variable slope (four parameter) curve fitting. One-way analysis 
of variance (ANOVA) was used to determine signifiance between the mean growth rates of the wild type, model, and sensor 
yeast strains. Residual analysis was used to provide an estimate of quality of the fitting of the Cell-Cell Digital model to the 
biological data, by which each residual is taken from the deviation of an observed value against the predicted value (Motulsky 
and Christopoulos, 2005). 
 
DATA AND SOFTWARE AVAILABILITY 
All part plasmids described in this paper are available at Addgene (Addgene ID: 123024-123065). Corrected nanopore 
sequencing reads for the yWS677 model strain are available at Sequence Read Archive (SRA) (SRA accession: 
PRJNA516326). MATLAB code for the mathematical models in this paper are available at BioModels Database (BioModels 




Figure S1. Cell Line Development. 
(A-C) Strategy for engineering the GPCR model strains. 
(A) To generate the 15 gene KOs in Figure 1D, double strand breaks (DSBs) were generated between the start and stop 
codon of the ORF of each gene using CRISPR/Cas9. Donor DNA was provided as a template for homology-directed repair 
(HDR), comprising 500 bp homology arms flanking a unique 20 bp Cas9 targeting sequence followed by a CGG protospacer 
adjacent motif (PAM) sequence. The resulting KOs represent a precise substitution of the open reading frame with a unique 
landing pad (LP) to enable future editing at each locus. A further 3 edits were performed at the URA3, LEU2, and HO loci 
to prepare the cells for efficient multiplexed integration of YTK plasmids by installing a landing pad between the two arms of 
homology. 
(B) To rapidly iterate through the 18 genomic edits a marker cycling strategy was employed. Once an edit, facilitated by 
CRISPR/Cas9 carried on a 2µ plasmid containing one of the three auxotrophic markers, URA3, LEU2 and HIS3, had been 
confirmed by colony PCR, the next set of edits would immediately be performed by transforming the donor DNA and 
CRISPR/Cas9 machinery supplied on a plasmid using the next marker in the cycle, removing the need to cure cells of the 
previous marker. A 3-marker cycle was sufficient to remove all trace of a marker before it was reused in the cycle. 
(C) Edits were implemented in a pairwise manner, totaling 8 rounds of editing to generate the yWS677 strain and an 
additional round to generate the yWS1922 strain. 12 colonies were screened for each pairwise edit, yielding at least one 
correct colony at each round. Editing of yWS677 and yWS1922 was followed by counterselection of the URA3 CRISPR 
apparatus by 5-FoA to generate clean strains. The final strain was validated for loss of all CRISPR plasmids via replica 
plating on Ura-, Leu- and His- media and colony PCR.  
(D+E) Nanopore sequencing of the yWS677 stain 
(D) De novo contigs assembled using Smartdenovo from reads corrected by Canu, representing the full set of 16 
chromosomes from S. cerevisiae, confirmed by exact alignment to S288C reference genome using a minimum alignment 
length of 100 bp. All discrepancies with the reference genome are highlighted and correspond to the 16 edits described in 
E. No other discrepancies were detected, suggesting precise CRISPR/Cas9 editing during the 8 rounds. 
(E) A list of the expected changes and confirmation of their correct positioning within the yWS677 genome. Note all 
alignments are approximately 1000 bp in length, as this was the size of the donor DNA transformed, except for STE3. Due 
to cloning issues with the STE3 KO donor DNA, a smaller fragment generated from oligonucleotides was used instead.  
(F-H) Efficient (Re)integration of DNA at the genomic CRISPR landing pads in yWS677. 
(F) Single, double, and triple integration of URA3, LEU2, and HIS3 maker cassettes at the URA3, LEU2, and HO loci, 
encoding sfGFP, mRuby2, and mTagBFP2, with and without Cas9 and the sgRNAs required to generate DSBs at their 
respective LP. 
(G) Green, red, and blue fluorescence of 96 random colonies from the CRIPSR-aided triple integration. 90/96 colonies 
correct for triple integration. The remaining 6 colonies contained a mixture of multiple integrations, or missing fluorescence 
proteins. Experimental measurements are sfGFP, mRuby2, and mTagBFP2 levels per cell determined by flow cytometry. 
(H) Colony PCR verification of the multiplexed re-integration of STE2, GPA1, and STE12 into yWS677 using markerless 
CRISPR/Cas9 editing to create the Quasi-WT strain. 8/10 random transformants were correct for the triple gene re-
integration. 5-FoA counter selection was used to cure a confirmed strain of the CRISPR plasmid, and direct Sanger 
sequencing of the 3 genes was performed to confirm their identity to validate the Quasi-WT strain. 
 

Figure S2. Initial Pathway Refactoring. 
(A) ɑ-factor dose-response curve of the pheromone response pathway in BY4741 (WT yeast), Quasi-WT, and Quasi-WT 
overexpressing Sst2, using the FUS1 promoter driving the expression of sfGFP. The poor response of BY4741 compared 
to Quasi-WT is due to the role of Sst2. 
(B-G) Here, we determine the promoter combinations for refactoring Ste2, Gpa1, and Ste12 in yWS677 (Ste4 and Ste18 
were refactored in yWS1922 after establishing the expression of Ste2, Gpa1, and Ste12 in yWS677). To do this, we 
substituted the native STE2, GPA1, and STE12 ORFs in yWS677 for the sfGFP ORF to serve as a proxy for native 
expression, enabling us to select promoter/terminator combinations from the YTK system for refactoring the minimized 
pheromone response pathway. 
(B) Before using YTK constitutive promoters, their performance under pheromone induction was measured to ensure it had 
no effect. 19 constitutive promoters from the YTK system were measured driving expression of sfGFP, with and without 
induction using 100 nM ɑ-factor peptide, in the Quasi-WT strain, after the standard assay time of 4 hours. 
(C) Relative fluorescence change (induced/uninduced) due to pheromone induction calculated from (B). A similar response 
was observed for all promoters, suggesting a common trait responsible for the increase in sfGFP fluorescence, likely caused 
by morphological changes as part of the pheromone response, leading to system wide increase in total protein. 
(D) Using LPs previously introduced at the gene KO sites, the sfGFP ORF was introduced between the native regulatory 
elements of STE2, GPA1, and STE12 to serve as a proxy for relative gene expression. 
(E) The GFP fluorescence levels of the STE2, GPA1, and STE12 ORF-GFP substitution strains were compared to the 19 
constitutive promoters of the YTK system also driving the expression of sfGFP, integrated at the URA3 locus of yWS677. 
The grey ellipse highlights 4 constitutive promoters with similar expression levels to the 3 genes; pSAC6, pPOP6, pRNR2, 
and pRAD27. 
(F) An expanded promoter/terminator library including all 6 terminators within the YTK toolkit in combination with the pSAC6, 
pPOP6, pRNR2, and pRAD27 promoters to provide a larger profile of sfGFP expression levels to match with the native 
expression of STE2, GPA1, and STE12. 
(G) Selection of promoter/terminator combinations both unique to each other and similar to native expression of STE2 
(green), GPA1 (blue), and STE12 (purple) chosen for the initial refactoring of the minimized pheromone response pathway 
(Figure 3, Design 1). 
(H) Characterizing two of the most used pheromone responsive promoters. ɑ-factor dose-response curve of the pheromone 
response pathway Quasi-WT background using the FUS1 and FIG1 promoters. As pFUS1 demonstrated more intrinsic leak 
this promoter was used to explore points of tuning in the pheromone response pathway, as discreet changes would be more 
measurable. 
Experimental measurements are sfGFP levels per cell determined by flow cytometry and shown as the mean ± standard 





Figure S3. Quantitative Plots of Ste2, Gpa1, and Ste4-2A-Ste18 Expression vs Pathway Output. 
(A) ɑ-factor dose-response of the minimized pathway designs where the intracellular levels of GPCR are varied using a 
promoter library driving the expression of Ste2. 
Promoter identity is plotted as heatmap of GFP fluorescence from data in Figure S2B. Experimental measurements are 
sfGFP levels per cell determined by flow cytometry and shown as the mean ± standard deviation from triplicate isolates. 
Curves were fitted using GraphPad Prism variable slope (four parameter) nonlinear regression fit. 
(B) Sensitivity of the Ste2 pathway variants to ɑ-factor. Sensitivity was determined from the fitted curve, defining sensitivity 
as the lowest concentration for which a >2-fold change in GFP expression is seen. 
(C) Experimental ON/OFF response of the minimized pathway designs where the intracellular levels of Gɑ are varied using 
a promoter library driving the expression of Gpa1. 
(D) Experimental maximum x-fold change in signal for Gpa1 promoter library. 
(E) Experimental ON/OFF response of the minimized pathway designs where the intracellular levels of Gβγ are varied using 
a promoter library driving the expression of Ste4-2A-Ste18. 
(F) Experimental maximum x-fold change in signal for Ste4-2A-Ste18 promoter library. 
Promoter identity is plotted as x-value of GFP fluorescence from data in Figure S2B. Curves fitting using a 6th order 
smoothing polynomial with 3 neighbors on each side. Experimental measurements are sfGFP levels per cell determined by 
flow cytometry and shown as the mean ± standard deviation from triplicate isolates. 
 

Figure S4.  Redirecting the Pheromone Response to Synthetic Promoters. 
(A+B) Experimental changes to the expression of Ste12. 
(A) A library of 17 constitutive promoters, from the YTK system, driving the expression of Ste12 with and without the 
overexpression of Dig1 and Dig2 in all combinations. The spotted yeast are direct transformants of two plasmids; the first 
containing the refactored pathway, with Ste12 under varying strengths of promoter, and the second containing either a blank 
spacer sequence, Dig1, Dig2, or Dig1 and Dig2 under the control of strong promoters. In the absence of Dig1 or Dig2 
overexpression, expressing Ste12 with anything greater than a low-medium strength promoter was toxic to the cells.  
(B) It has previously been reported that Dig1 and Dig2 sit in a fine balance with Ste12, and the presence of these two 
negative regulators positively affect transcription by stabilizing inactive Ste12 (Houser et al., 2012). These data support 
these findings and suggests that increasing the concentration of Ste12 in the cells may lead to a large pool of unregulated 
transcription factor that may be constitutively activating the 100+ genes usually upregulated in the pheromone response, 
leading to cellular burden and toxicity (Dolan and Fields, 1990). As there is a fine balance between Ste12 and the two 
negative regulators, tuning the maximum signal output via the expression of Ste12 would require parallel tuning of both Dig1 
and Dig2. Due to the combinatorial complexity of this problem we chose alternative approaches for modulating the signal 
amplitude and kept the expression Ste12 and synthetic transcription factors fixed at low levels using the RAD27 promoter. 
(C) Decoupling the pheromone response pathway from PRE-containing genes using the LexA-PRD transcription factor 
targeting a synthetic promoter (LexO(6X)-pLEU2m). Fold-change in transcription of the refactored components, STE2, 
GPA1 and STE2/sTF, the negative regulators of Ste12, DIG1 and DIG2, and several of the most highly-upregulated genes 
in the pheromone response, FIG1, PRM2, CIK1 (Su et al., 2010), in the Quasi-WT and Design 4 strains, with and without 
pheromone induction, as determined by RT-qPCR. The dotted line represents no fold-change. 
(D-G) Sensitivity of the Quasi-WT response is largely due to Ste12-mediated transcriptional feedback of Ste2, Gpa1, and 
Ste12. 
(D) Native transcriptional feedback of the Ste2, Gpa1, and Ste12 in the pheromone response pathway after stimulation. 
(E) Linear range within a time-course experiment measuring sfGFP fluorescence from STE2, GPA1, and STE12 regulatory 
elements after stimulation with 100 nM ɑ-factor, fitted with a linear curve. The third minimized pathway (Figure 4C, Design 
3) was used to upregulate native gene expression in response to ɑ-factor. 
(F) Model of Ste2 and Gpa1 feedback using different strengths of positive feedback on the expression of Ste2 and Gpa1, 
using values for Ste2 feedback 1 order of magnitude greater than Gpa1 as determined by the time-course experiments.  
(G) Reconstructing the Quasi-WT response in the first minimized pathway design by introducing transcriptional feedback of 
Ste2, Gpa1, and Ste12, controlled by the pheromone inducible FUS1 promoter. The differences between Design 1 and 
Quasi-WT seems to be largely due to the positive feedback of native Ste12-activated promoters for Ste2, Gpa1, and Ste12. 
(H) Overexpression of Ste2 in the Design 4 strain with one or two additional integration vectors expressing Ste2 from a 
strong promoter (pCCW12). Although 2x and 3x Ste2 should be present in the system, the activation at 1e-10 M ɑ-factor 
remains unchanged. This also seems to be the limit for the Quasi-WT response, suggesting the receptor is at the physical 
limit of ɑ-factor detection and further Ste2 in the system will not be able to detect lower than this value. 
(I+J) Growth rates of the wild type, model, and refactored strains. 
(I) Growth rates of the base strains, demonstrating no significant difference between BY4741 parental strain and the yWS677 
strain. However, a significant increase in growth was seen in the yWS1922 strain compared to both BY4741 and yWS677. 
(J) Growth rates of the Quasi-WT and Design 4 Ste2 overexpression strains, demonstrating no significant difference between 
the four strains. 
Experimental measurements are sfGFP levels per cell determined by flow cytometry and shown as the mean ± standard 
deviation from triplicate isolates. Unless indicated, curves were fitted using GraphPad Prism variable slope (four parameter) 
nonlinear regression fit. GraphPad Prism one-way analysis of variance (ANOVA) used to determine statistical significance 
between growth rates (*P < 0.05, **P < 0.005, ***P < 0.0005). 
 
  
Figure S5. Final GPCR-Based Sensor Toolkit Format, Parts List, and Workflow. 
Here, a module refers to either a cassette or multigene cassette that integrates into the yeast genome at one of the 3 sites 
provided in the YTK system starter set (URA3, LEU2 or HO loci). All parts and cloning steps conform to the YTK MoClo 
standard (Lee et al., 2015). 
(A) A list of parts and formatting of the multigene cassette used for generating the minimized GPCR pathway (URA3 module) 
which integrates at the URA3 loci, indicating the instances where promoters (pYTK) and terminators (tYTK) from the YTK 
system are used. Spacer sequences are provided to exclude components in the instances where they are not required. 
Alternatively, components can be transferred to the additional LEU2 or HO modules for combinatorial pathway refactoring, 
to reduce cloning requirements. 
(B) Additional parts for use with the LEU2 and HO modules, for integrating at LEU2 and HO loci, respectively. 
(C) Assembling and integrating the URA3 module for generating a minimized GPCR sensor in the yWS677 model strain, 
following the YTK hierarchical assembly strategy (see Lee et al. (2015) for more details). 
(D) Multiple modules can be integrated simultaneously with the aid of CRISPR/Cas9-mediated DSB at the URA3, LEU2 and 
HO landing pads. Once co-transformed with the other modules, the transient expression of Cas9 and appropriate gRNAs 
(no yeast marker or replicon) significantly increases the efficiency of double and triple plasmid integrations to practical levels 
(See Figure S1F+S1G). 
 
 
Figure S6. Linearizing and Digitizing the A2BR and MTNR1A sensors using intracellular feedback loops. 
(A-D) Screening the A2BR and MTNR1A receptors against a chimeric Gpa1-Gɑ library to identify optimal coupling to the 
pheromone response pathway. Sensors were created using the optimized conditions identified for Design 4, taking less than 
a week to create. 
(A) Coupling of the A2BR receptor to the Gpa1-Gɑ library in the presence and absence of saturating concentrations of 
adenosine (100 µM). 
(B) Coupling of the MTNR1A receptor to the chimeric Gpa1-Gɑ library in the presence and absence of saturating 
concentrations of melatonin (100 µM). As the wild-type Gpa1 coupled well to both A2BR and MTNR1A all future experiments 
were performed using this G protein. 
(C) Adenosine dose-response curve of the A2BR sensor strain, demonstrating a comparatively high Hill slope. 
(D) Melatonin dose-response curve of the MTNR1A sensor strain, demonstrating a comparatively low Hill slope. 
(E-L) Overlaying synthetic feedback (FB) loops onto the minimized sensing pathway to achieve linearization and digitization 
of A2BR and MTNR1A, respectively. 
(E) Negative feedback loops using the expression of Sst2, Gpa1, Msg5, and Dig1 as an output of pathway activation 
(Bardwell, 2004; Bashor et al., 2008; Galloway et al., 2013). 
(F+G) Feedback of negative regulators of the pheromone response pathway to linearize the dose-response of the A2BR 
receptor. 
(H) Hill slope values from the normalized curves of the 4 negative feedback conditions and no feedback control. Although 
feedback of the negative regulators had a significant impact on the response, when the output of each response was 
normalized, the effect on the Hill slope was minimal. 
(I) Positive feedback loops using the expression of Ste50, Ste4-2A-Ste18, and MTNR1A receptor as an output of pathway 
activation (Bardwell, 2004; Bashor et al., 2008; Galloway et al., 2013). Although Ste11 has been demonstrated as a viable 
candidate for positive feedback, it was omitted from the list as it was also shown to cause a large fitness defect when used 
in this manner (Ingolia and Murray, 2007). 
(J+K) Feedback of positive regulators of the pheromone response pathway to digitize the dose-response of the MTNR1A 
receptor. 
(L) Hill slope values from the normalized curved of the 3 positive feedback conditions and no feedback control. Feedback 
of these signaling components had a very small effect on the response of the system. 
Experimental measurements are sfGFP levels per cell determined by flow cytometry and shown as the mean ± standard 




Figure S7. Linearizing and digitizing the A2BR and MTNR1A response, respectively. 
(A+B) Unnormalized sfGFP fluorescence is used to account for differences in growth rate between strains. 
(A) Adenosine dose-response of several adenosine sensors expressing A2BR using the weak RPL18B (low sensitivity), 
medium HHF2 (mid sensitivity), and strong CCW12 (high sensitivity) promoters. Experimental measurements are sfGFP 
levels per cell determined by flow cytometry and shown as the mean ± standard deviation from triplicate isolates. 
(B) Adenosine dose-dependent OD measurements of the three different sensitivity A2BR sensor strains after the standard 
6 h assay time. To account for any differences in the growth rate between the different strains when activated or inactive, 
all future sfGFP measurements for experiments using microbial consortia were taken as the unnormalized fluorescence of 
the population using a plate reader. All strains set up at the starting OD of 0.175 at time 0 h and measurements were taken 
at 6 h. In this way, sfGFP fluorescence represents both growth rate and sfGFP production rate. 
(C-E) Tuning the expression of Bar1 in the two-cell amplifier-reporter system. 
(C) Varying the concentration of Bar1 in the two-cell amplifier-reporter model. 
(D) Experimentally varying the expression of Bar1 in the two-cell amplifier-reporter system using a select promoter library.  
(E) Hill slope values from computationally and experimentally varying the levels of Bar1 in the amplifier-reporter system. 
(F-H) Digitising and fine-tuning the MTNR1A sensor response. 
(F) Melatonin dose-response of the MTNR1A sensor strain in a monogenic population of cells. 
(G) Digitisation of the MTNR1A response via ɑ-factor mediated cell-cell communication. In response to melatonin, the first 
cell produces large quantities of ɑ-factor peptide that is then detected by the second cell, which responds by producing 
sfGFP. 
(H) Fine tuning the MTRN1A digital response by reducing the receptor expression in the first cell, so that the logEC50 
matches the response of the single cell system. By lowering the expression of the MTNR1A receptor in the first cell using 
the ALD6 promoter, we were able to shift the potency (logEC50) of the melatonin dose-response right by 1.5 orders of 
magnitude, to match the potency of the first, single cell system, while maintaining a high Hill slope. 
Data normalised to the minimum and maximum values within each dataset.  Unnormalized, raw fluorescence readings were 
taken using a plate reader to account for growth during the 6h assay. Results are means ± standard deviation from triplicate 
isolates. 
Experimental measurements are sfGFP levels determined by a plate reader and shown as the mean ± standard deviation 
from triplicate isolates. Curves were fitted using GraphPad Prism variable slope (four parameter) nonlinear regression fit. 
 

Figure S8. Model Schematics. 
(A) The detailed reaction scheme of the cubic ternary complex model modified for the refactored S. cerevisiae pathway. 
Reactions can be divided into modules of which involves Receptor activation (Top) and G protein cycle (Bottom). Black 
letters each represent a species within a system, and all arrows are marked in red letters with rate constants k● and 
corresponding cooperativity factors μ, ν, and ζ, which produce a unique rate constant for each reaction. 
(B) The detailed reaction scheme of the single ternary complex model modified for the refactored S. cerevisiae pathway. 
Reactions can be divided into modules of which involves Receptor activation (Top), G protein cycle (Middle), and the 
downstream cascade (Bottom). Black letters each represent a species within a system, and all arrows are marked in red 
letters with rate constants k● and corresponding cooperativity factors μ, ν, and ζ, which produce a unique rate constant for 
each reaction. 
(C) Schematic diagram of the double cell system. (Left) Signaling system within a cell. Each cell contains the corresponding 
set of kinetic rates and species. (Right) Simplified version of the full system, including the interaction of Bar1 and α-factor 
and its degradation. 
(D) Overall fitting results against time course data as concentration-response curves taken through endpoint readings. Solid 
shapes represent experimental results reading fluorescence 260 minutes after the addition of ligand. Solid lines represent 
ODE results derived from time courses of 260 minutes. Blue represents the system with the α-factor producing cell only and 
red represents the system with two cells with Bar1. 
(E) Residual plots of the experimental concentration-response curves against the computational fitting results. (Left) 
Residual plots of the MTNR1A sensor. (Middle) Residual plots of the experimental results of digital feedback without Bar1. 
(Right) Residual plots of the experimental results of digital feedback with Bar1. 








Sub-class GPCR name Species Ligand Reference 
5-Hydroxytryptamine receptors 5-HT4 receptor Human Serotonin (Ehrenworth et al., 2017) 
Acetylcholine receptors (muscarinic) M1 receptor  Human Acetylcholine (Erlenbach et al., 2001a) 
M3 receptor  Rat Acetylcholine (Erlenbach et al., 2001a) 
M5 receptor  Human Acetylcholine (Erlenbach et al., 2001a) 
Adenosine receptors A1 receptor  Human Adenosine (Campbell et al., 1999) 
A2A receptor  Human Adenosine (Campbell et al., 1999) 
A2B receptor  Human Adenosine (Brown et al., 2000) 
Adrenoceptors β2-adrenoceptor Human Epinephrine (King et al., 1990) 
Adrenomedullin AM1 receptor  Human Adrenomedullin (Miret et al., 2002) 
AM2 receptor  Human Adrenomedullin (Miret et al., 2002) 
Cannabinoid receptors CB1 receptor  Human Cannabinoids (Brown et al., 2011) 
CB2 receptor Human Cannabinoids (Brown et al., 2011) 
CGRP CGRP receptor  Human CGRP (Miret et al., 2002) 
Chemokine receptors CXCR4 Human SDF1 (Evans et al., 2009) 
Class A Orphans GPR119 Human Oleoylethanolamide  (Overton et al., 2006) 
GPR35 Human Cannabinoids (Brown et al., 2011) 
GPR55 Human Cannabinoids (Brown et al., 2011) 
Complement peptide receptors C5a1 receptor  Human  (Baranski et al., 1999) 
Dopamine receptor D2S Human Dopamine (Sander et al., 1994) 
Formylpeptide receptors FPR1  Human Formylpeptide (Klein et al., 1998) 
Free fatty acid receptors FFA2 Receptor Human Short-chain fatty acids (Brown et al., 2003) 
FFA3 Receptor Human Short-chain fatty acids (Brown et al., 2003) 
GPR40 Human Medium-chain fatty acids (Mukherjee et al., 2015) 
Glucagon receptor family GHRH receptor  Human GHRH (Kajkowski et al., 1997) 
GCGR receptor Human Glucagon (Weston et al., 2015) 
GLP-1 receptor  Human GLP-1 (Weston et al., 2014) 
Hydroxycarboxylic acid receptors HCA2 receptor  Human Niacin (Liu et al., 2016) 
HCA3 receptor  Human Niacin (Liu et al., 2016) 
Lysophosphatidic acid (LPA) receptors LPA receptor 1  Human Lysophosphatidic acid (Erickson et al., 1998) 
Melatonin receptors MT1 receptor  Human Melatonin (Kokkola et al., 1998) 
MT2 receptor  Human Melatonin (Brown et al., 2000) 
Neurotensin NTS1 receptor  Human Neurotensin (Leplatois et al., 2001) 
Olfactory receptor OR1G1 Human Medium chain fatty acids (Mukherjee et al., 2015) 
Opioid receptor MOR receptor Human Opioids (Gaibelet et al., 1999) 
Orphan receptors GPR68 Human Benzodiazepine (Huang et al., 2015) 
P2Y receptors P2Y1 receptor  Human Nucleotides (Brown et al., 2000) 
P2Y1 receptor  Human Nucleotides (Brown et al., 2000) 
P2Y14 receptor  Human UDP-glucose (Chambers et al., 2000) 
Peptide pheromone receptors RCb2 C. cinerus Peptide pheromone (Olesnicky et al., 1999) 
RCb3 C. cinerus Peptide pheromone (Olesnicky et al., 1999) 
Bbr1, 2 S. commune Peptide pheromone (Fowler et al., 1999) 
FLP2 C. elegans Peptide pheromone (Larsen et al., 2013) 
Ce.Ste2 C. glabrata Peptide pheromone (Ostrov et al., 2017) 
Ca.Ste2 C. albicans Peptide pheromone (Ostrov et al., 2017) 
Le.Ste2 L. elongisporus Peptide pheromone (Ostrov et al., 2017) 
Pb.Ste2 P. brasiliensis Peptide pheromone (Ostrov et al., 2017) 
Bc.Ste2 B. cinerea Peptide pheromone (Ostrov et al., 2017) 
Fg.Ste2 F. graminearum Peptide pheromone (Ostrov et al., 2017) 
Mo.Ste2 M. oryzae Peptide pheromone (Ostrov et al., 2017) 
Zb.Ste2 Z. bailii Peptide pheromone (Ostrov et al., 2017) 
Zr.Ste2 Z. rouxii Peptide pheromone (Ostrov et al., 2017) 
Rhodopsin  RHO receptor Human Light (Scott et al., 2018) 
Somatostatin receptors SST2 receptor Human Somatostatin (Brown et al., 2000) 
SST2 receptor Rat Somatostatin (Price et al., 1995) 
SST5 receptor  Human Somatostatin (Brown et al., 2000) 
Vasopressin V2 receptor  Human Vasopressin (Erlenbach et al., 2001b) 
Table S2. Oligonucleotides Used in this Study. 
SST2 KO seq./colony PCR FP CGAATTTTTGAAGGTCTTTCC 
SST2 KO colony PCR RP CGAGGTGGACTACGATTGC 
SST2 KO seq. RP ATCAAAGAATCACCCAATTCC 
FAR1 KO seq./colony PCR FP CATTCATACGATGGTGAACAG 
FAR1 KO colony PCR RP CCGCCTCATTTCTAAGTACG 
FAR1 KO seq. RP AGTACACGCTGACCCGTT 
BAR1 KO seq./colony PCR FP TGGAAGGTCGTAGCAAGG 
BAR1 KO colony PCR RP CGTGCGACTTGCTAACC 
BAR1 KO seq. RP aataccggggtgtcttgac 
STE12 KO seq./colony PCR FP AACGAACGTTAAGGAACCC 
STE12 KO colony PCR validation CGGAAGTAGGAAGCGATG 
STE12 KO seq. RP GCTTTTTCCTTTGGCTTACC 
STE2 KO seq./colony PCR FP ATCTTCCCTTCCCAGAGAG 
STE2 KO colony PCR validation CCGCGTACTAACACGAAAG 
STE2 KO seq. RP AATATGACGTTGCTTCTGCTT 
GPA1 KO seq./colony PCR FP GCTGTTTTACTCGACTCAACG 
GPA1 KO colony PCR validation CTGCTTGTGTCACCATGC 
GPA1 KO seq. RP CTTGAGGAGTGGTCGTACTG 
GPR1 KO seq./colony PCR FP GACGATAGAGTCCTTGGGAG 
GPR1 KO colony PCR RP GCCAAAGTCGACGGTTAG 
GPR1 KO seq. RP AAAGGTCCTGTACGTAAAATGG 
GPA2 KO seq./colony PCR FP AGCTGCCATTCTTATGATACTG 
GPA2 KO colony PCR RP TTCCGATGCAGGATAACAG 
GPA2 KO seq. RP TCAAAAGCTCCTGGTTCCT 
MF(ALPHA)1 KO seq./colony PCR FP CTTCTTTTCTTGAGGAGAGATCC 
MF(ALPHA)1 KO colony PCR RP TGGTTTTGGGAACTCGTG 
MF(ALPHA)1 KO seq. RP TCAGAACATGAGATCAACGG 
MF(ALPHA)2 KO seq. FP TGTTGTTCTTATTTGAGCGAAC 
MF(ALPHA)2 ORF KO colony PCR RP GATATGCTGGCCTATCGG 
MF(ALPHA)2 KO seq. RP CACAAGTCGGAGGAGAGC 
MFA1 KO seq./colony PCR FP AGATGCTGTACCGTTCACG 
MFA1 colony PCR RP AGCTGATGAGCGTTACTGC 
MFA1 KO seq. RP TGCATATTTCACAATAAAGACAGTC 
MFA2 KO seq./colony PCR FP ATTCATACTCATAATGTTGATATTTCG 
MFA2 colony PCR RP ACCGTCCTTGATCTCCAG 
MFA2 KO seq. RP AATCAATCCAGTAACGATTCG 
STE3 KO seq./colony PCR FP CTAGTAGACCGGCCAAGC 
STE3 colony PCR RP CCGCTTGGACAAGAAACA 
STE3 KO seq. RP CCCAAGATAATATCATTTGTTACG 
URA3 LP seq./colony PCR FP CGTGTAAGCAGATAAGTGAATTTG 
URA3 LP colony PCR RP CGCGGTAGGTGTACAATAATATT 
URA3 LP seq. RP CCCATATCCAACTTCCAATTTA 
LEU2 LP seq./colony PCR FP CTATGTGGTATTCGATTATGCG 
LEU2 LP colony PCR RP ATGCTAGTCCACCTGATGC 
LEU2 LP seq. RP CGTGGAAGGAGAATCTTTATTG 
HO LP seq./colony PCR FP ATTCACATCATTTTCGTGGATC 
HO LP colony PCR RP GGTGAAGCATTTCGTCCAT 
HO LP seq. RP CCTTTGGACTTAAAATGGCG 
STE4 KO validation/seq FP CGCACTTTCGTCAGATGCA 
STE4 KO validation RP GAAGCTAACCGCGGCATC 
STE4 KO seq RP AATCATCCCAGAAGGGAGCAG 
STE18 KO validation/seq FP CACCTTTTCATCAACCCCGT 
STE18 KO validation RP CATTAACCGTGGCTAGTCGTCTATG 
STE18 KO seq RP AGACAACTTCCAAGAACTTGAGCC 
Validation of CRISPR plasmid loss FP ccgataattgcagacgaac 
Validation of CRISPR plasmid loss RP cccgacgctattagtccc 
sfGFP FP for Ste2 donor TTAAAAATGCACCGTTAAGAACCATATCCAAGAATCAAAAATGtccaagggtgaagag 
sfGFP RP for Ste2 donor GGTCACGAAATTACTTTTTCAAAGCCGTAAATTTTGATCActtataaagctcgtccattc 
sfGFP FP for Gpa1 donor ATCCAGAGGTGTATAAATTGATATATTAAGGTAGGAAATAATGtccaagggtgaagag 
sfGFP RP for Gpa1 donor TTACGTATCTAAACACTACTTTAATTATACAGTTCCTTCActtataaagctcgtccattc 
sfGFP FP for Ste12 donor GGAACCGCTTTCTTTATTTGAATTGTCTTGTTCACCAAGGATGtccaagggtgaagag 
sfGFP RP for Ste12 donor TTAATTCTTGTATCATAAATTCAAAAATTATATTATATCActtataaagctcgtccattc 
STE2 qPCR FP CTCAAGCAGTTCGATAGTTTCC 
STE2 qPCR RP GACATCTGTTCCCTGGTTTG 
GPA1 qPCR FP GACTTGAACCAAGAAGGCG 
GPA1 qPCR RP GCCTTAGCAATGTCTTCGTG 
STE12 qPCR FP CCACCATCATCATCGAGG 
STE12 qPCR RP CATACTTCATGTAGCTGGTAGGGT 
DIG1 qPCR FP CTGGGAAAACCAGACGATC 
DIG1 qPCR RP CTGCTGGGCGTAGATCC 
DIG2 qPCR FP GGGTCAGATATATGGGTAGGATG 
DIG2 qPCR RP GGTGGCAGTCCAGTATATGG 
HTB2 qPCR FP AAGCAAACTCACCCAGACAC 
HTB2 qPCR RP AGCGGCCAATTTAGAAGC 
FIG1 qPCR FP AAGAATTTAAGCTCGGTTCCC 
FIG1 qPCR RP TCAAAATGTTCAAGACAACGC 
PRM2 qPCR FP CATTCCACAAAAGAGCGG 
PRM2 qPCR RP TTTTCACACAATAATGATACGCTG 
CIK1 qPCR FP AAAGACCTACAAGACACCCATG 
CIK1 qPCR RP TCACTTCTGCCTCTCCAATC 
sfGFP qPCR FP attctcggccataaacttgag 
sfGFP qPCR RP cttcgacgttgtgcctg 
SST2 5' gRNA Sense 
(AAGATAGAGTTGTAAGATGG)  gactttAAGATAGAGTTGTAAGATGG 
SST2 5' gRNA Antisense 
(AAGATAGAGTTGTAAGATGG)  aaacCCATCTTACAACTCTATCTTaa 
SST2 3' gRNA Sense 
(AATGAAATTAGCACTTTTCT) gactttAATGAAATTAGCACTTTTCT 
SST2 3' gRNA Antisense 
(AATGAAATTAGCACTTTTCT) aaacAGAAAAGTGCTAATTTCATTaa 
FAR1 5' gRNA Sense 
(TTTTCAAACGAAACTCTTGT) gactttTTTTCAAACGAAACTCTTGT 
FAR1 5' gRNA Antiense 
(TTTTCAAACGAAACTCTTGT) aaacACAAGAGTTTCGTTTGAAAAaa 
FAR1 3' gRNA Sense 
(CTAGAGGTTGGGAACTTCCA) gactttCTAGAGGTTGGGAACTTCCA 
FAR1 3' gRNA Antisense 
(CTAGAGGTTGGGAACTTCCA) aaacTGGAAGTTCCCAACCTCTAGaa 
BAR1 5' gRNA Sense 
(TCTTTGTTTGAAACTTATTT) gactttTCTTTGTTTGAAACTTATTT 
BAR1 5' gRNA Antisense 
(TCTTTGTTTGAAACTTATTT) aaacAAATAAGTTTCAAACAAAGAaa 
BAR1 3' gRNA Sense 
(GTTATGACTGTCTTATGAGT) gactttGTTATGACTGTCTTATGAGT 
BAR1 3' gRNA Antiense 
(GTTATGACTGTCTTATGAGT) aaacACTCATAAGACAGTCATAACaa 
STE2 5' gRNA Sense 
(TTGCAACTCATCGAAAGTGA) gactttTTGCAACTCATCGAAAGTGA 
STE2 5' gRNA Antisense 
(TTGCAACTCATCGAAAGTGA) aaacTCACTTTCGATGAGTTGCAAaa 
STE2 3' gRNA Sense 
(GCTGATGCAAGTTACAAAGA) gactttGCTGATGCAAGTTACAAAGA 
STE2 3' gRNA Antisense 
(GCTGATGCAAGTTACAAAGA) aaacTCTTTGTAACTTGCATCAGCaa 
STE12 5' gRNA Sense 
(AATAACCAATAGTAGAACAG) gactttAATAACCAATAGTAGAACAG 
STE12 5' gRNA Antisense 
(AATAACCAATAGTAGAACAG) aaacCTGTTCTACTATTGGTTATTaa 
STE12 3' gRNA Sense 
(GTTTTTATCGGACCTTCGAT) gactttGTTTTTATCGGACCTTCGAT 
STE12 3' gRNA Antisense 
(GTTTTTATCGGACCTTCGAT) aaacATCGAAGGTCCGATAAAAACaa 
GPA1 5' gRNA Sense 
(ACAGTGAGTACGCAAACAAT) gactttACAGTGAGTACGCAAACAAT 
GPA1 5' gRNA Antisense 
(ACAGTGAGTACGCAAACAAT) aaacATTGTTTGCGTACTCACTGTaa 
GPA1 3' gRNA Sense 
(GTTTTGCTGGATGATTAGAT) gactttGTTTTGCTGGATGATTAGAT 
GPA1 3' gRNA Antisense 
(GTTTTGCTGGATGATTAGAT) aaacATCTAATCATCCAGCAAAACaa 
MF(ALPHA)1 5' gRNA Sense 
(AAAACTGCAGTAAAAATTGA) gactttAAAACTGCAGTAAAAATTGA 
MF(ALPHA)1 5' gRNA Antisense 
(AAAACTGCAGTAAAAATTGA) aaacTCAATTTTTACTGCAGTTTTaa 
MF(ALPHA)1 3' gRNA Sense 
(CATTGGTTGCAGTTAAAACC) gactttCATTGGTTGCAGTTAAAACC 
MF(ALPHA)1 3' gRNA Antisense 
(CATTGGTTGCAGTTAAAACC) aaacGGTTTTAACTGCAACCAATGaa 
MF(ALPHA)2 5' gRNA Sense 
(CGCTAAAATAAAAGTGAGAA) gactttCGCTAAAATAAAAGTGAGAA 
MF(ALPHA)2 5' gRNA Antisense 
(CGCTAAAATAAAAGTGAGAA) aaacTTCTCACTTTTATTTTAGCGaa 
MF(ALPHA)2 3' gRNA Sense 
(CACTGGTTGCAACTCAAGCC) gactttCACTGGTTGCAACTCAAGCC 
MF(ALPHA)2 3' gRNA Antisense 
(CACTGGTTGCAACTCAAGCC) aaacGGCTTGAGTTGCAACCAGTGaa 
MFA1 gRNA Sense 
(GGTCTTTTCTTTTGGAGCGG) gactttGGTCTTTTCTTTTGGAGCGG 
MFA1 gRNA Antisense 
(GGTCTTTTCTTTTGGAGCGG) aaacCCGCTCCAAAAGAAAAGACCaa 
MFA2 gRNA Sense 
(ATAGTTGTCTTTCTTTTCAG) gactttATAGTTGTCTTTCTTTTCAG 
MFA2 gRNA Antisense 
(ATAGTTGTCTTTCTTTTCAG) aaacCTGAAAAGAAAGACAACTATaa 
STE3 5' gRNA Sense 
(CATACAAGTCAGCAATAATA) gactttCATACAAGTCAGCAATAATA 
STE3 5' gRNA Antisense 
(CATACAAGTCAGCAATAATA) aaacTATTATTGCTGACTTGTATGaa 
STE3 3' gRNA Sense 
(CATAGTTCAGAAAATACTGC) gactttCATAGTTCAGAAAATACTGC 
STE3 3' gRNA Antisense 
(CATAGTTCAGAAAATACTGC) aaacGCAGTATTTTCTGAACTATGaa 
GPR1 5' gRNA Sense 
(TTCAACGCGTTTAAATTCGG) gactttTTCAACGCGTTTAAATTCGG 
GPR1 5' gRNA Antiense 
(TTCAACGCGTTTAAATTCGG) aaacCCGAATTTAAACGCGTTGAAaa 
GPR1 3' gRNA Sense 
(AATGATAGTAGTGATAGTAG) gactttAATGATAGTAGTGATAGTAG 
GPR1 3' gRNA Antisense 
(AATGATAGTAGTGATAGTAG) aaacCTACTATCACTACTATCATTaa 
GPA2 5' gRNA Sense 
(TGCGCATCTTCAGAAAAGAA) gactttTGCGCATCTTCAGAAAAGAA 
GPA2 5' gRNA Antisense 
(TGCGCATCTTCAGAAAAGAA) aaacTTCTTTTCTGAAGATGCGCAaa 
GPA2 3' gRNA Sense 
(GAAAATACATTGAAAGACTC) gactttGAAAATACATTGAAAGACTC 
GPA2 3' gRNA Antisense 
(GAAAATACATTGAAAGACTC) aaacGAGTCTTTCAATGTATTTTCaa 
URA3 gRNA Sense 
(TCAGGGTCCATAAAGCTCCC) gactttTCAGGGTCCATAAAGCTCCC 
URA3 gRNA Antisense 
(TCAGGGTCCATAAAGCTCCC) aaacGGGAGCTTTATGGACCCTGAaa 
LEU2 1/2 gRNA Sense 
(TTACTACTATATATTATTGT) gactttTTACTACTATATATTATTGT 
LEU2 1/2 gRNA Antisense 
(TTACTACTATATATTATTGT) aaacACAATAATATATAGTAGTAAaa 
LEU2 2/2 gRNA Sense 
(CCTCTAATCATGAATGTTCT) gactttCCTCTAATCATGAATGTTCT 
LEU2 2/2 gRNA Antisense 
(CCTCTAATCATGAATGTTCT) aaacAGAACATTCATGATTAGAGGaa 
HO gRNA Sense 
(GCTCCAGCATTATAGCATGC) gactttGCTCCAGCATTATAGCATGC 
HO gRNA Antisense 
(GCTCCAGCATTATAGCATGC) aaacGCATGCTATAATGCTGGAGCaa 
STE4 5’ gRNA Sense 
(TTGTGGTTGTATATACTGTT) gactttTTGTGGTTGTATATACTGTT 
STE4 5’ gRNA Antisense 
(TTGTGGTTGTATATACTGTT)  aaacAACAGTATATACAACCACAAaa 
STE4 3’ gRNA Sense 
(ACCATGAAAATATGGTCTCC) gactttACCATGAAAATATGGTCTCC 
STE4 3’ gRNA Antisense 
(ACCATGAAAATATGGTCTCC) aaacGGAGACCATATTTTCATGGTaa 
STE18 5’ gRNA Sense 
(TCCTGAGGTTGTTGTAAGCG) gactttTCCTGAGGTTGTTGTAAGCG 
STE18 5’ gRNA Antisense 
(TCCTGAGGTTGTTGTAAGCG) aaacCGCTTACAACAACCTCAGGAaa 
STE18 3’ gRNA Sense 
(CACTATTTGAGTTTGACATT) gactttCACTATTTGAGTTTGACATT 
STE18 3’ gRNA Antisense 
(CACTATTTGAGTTTGACATT) aaacAATGTCAAACTCAAATAGTGaa 
URA3 LP gRNA Sense 
(ATATTATTGTACACCTACCG) gactttATATTATTGTACACCTACCG 
URA3 LP gRNA Antisense 
(ATATTATTGTACACCTACCG) aaacCGGTAGGTGTACAATAATATaa 
LEU2 LP gRNA Sense 
(GCATCAGGTGGACTAGCATG) gactttGCATCAGGTGGACTAGCATG 
LEU2 LP gRNA Antisense 
(GCATCAGGTGGACTAGCATG) aaacCATGCTAGTCCACCTGATGCaa 
HO LP gRNA Sense 
(ATGGACGAAATGCTTCACCA) gactttATGGACGAAATGCTTCACCA 
HO LP gRNA Antisense 
(ATGGACGAAATGCTTCACCA) aaacTGGTGAAGCATTTCGTCCATaa 
STE2 KO LP gRNA Sense 
(CTAGCTTTCGTGTTAGTACG) gactttCTAGCTTTCGTGTTAGTACG 
STE2 KO LP gRNA Antisense 
(CTAGCTTTCGTGTTAGTACG) aaacCGTACTAACACGAAAGCTAGaa 
STE12 KO LP gRNA Sense 
(CATCGCTTCCTACTTCCGCT) gactttCATCGCTTCCTACTTCCGCT 
STE12 KO LP gRNA Antisense 
(CATCGCTTCCTACTTCCGCT) aaacAGCGGAAGTAGGAAGCGATGaa 
GPA1 KO LP gRNA Sense 
(TAGCATGGTGACACAAGCAG) gactttTAGCATGGTGACACAAGCAG 
GPA1 KO LP gRNA Antisense 
(TAGCATGGTGACACAAGCAG) aaacCTGCTTGTGTCACCATGCTAaa 
Gpa1 Sense (KIGII) GAAAaaaattggtattattTAACTCGAG 
Gpa1 Antisense (KIGII) GCCACTCGAGTTAaataataccaatttt 
Gαs/olf Sense (QYELL) GAAAcaatatgagctacttTAACTCGAG 
Gαs/olf Antiense (QYELL) GCCACTCGAGTTAaagtagctcatattg 
Gα12 Sense (DIMLQ) GAAAgatattatgttgcaaTAACTCGAG 
Gα12 Antisense (DIMLQ) GCCACTCGAGTTAttgcaacataatatc 
Gα13 Sense (QLMLQ) GAAAcaattgatgttgcaaTAACTCGAG 
Gα13 Antisense (QLMLQ) GCCACTCGAGTTAttgcaacatcaattg 
Gαi1/2 (Gnat) Sense (DCGLF) GAAAgattgtggtttgtttTAACTCGAG 
Gαi1/2 (Gnat) Antisense (DCGLF) GCCACTCGAGTTAaaacaaaccacaatc 
Gαi3 Sense (ECGLY) GAAAgaatgtggtttgtatTAACTCGAG 
Gαi3 Antisense (ECGLY) GCCACTCGAGTTAatacaaaccacattc 
Gαz Sense (YIGLC) GAAAtatattggtttgtgtTAACTCGAG 
Gαz Antisense (YIGLC) GCCACTCGAGTTAacacaaaccaatata 
Gα15/16 Sense (EINLL) GAAAgaaattaatttgttgTAACTCGAG 
Gα15/16 Antisense (EINLL) GCCACTCGAGTTAcaacaaattaatttc 
Gαq/11 Sense (EYNLV) GAAAgagtataacttggtcTAACTCGAG 
Gαq/11 Antisense (EYNLV) GCCACTCGAGTTAgaccaagttatactc 
Gα14 Sense (EFNLV) GAAAgaatttaatttggttTAACTCGAG 
Gα14 Antisense (EFNLV) GCCACTCGAGTTAaaccaaattaaattc 
Gαo Sense (GCGLY) GAAAggttgtggtttgtatTAACTCGAG 
Gαo Antisense (GCGLY) GCCACTCGAGTTAatacaaaccacaacc 
Sp gpa1 Sense (QSLMF) GAAAcaatctttgatgtttTAACTCGAG 
Sp gpa1 Antisense (QSLMF) GCCACTCGAGTTAaaacatcaaagattg 
 
Table S3. Part Sequences. 
Part sequences in YTK format (Lee et al., 2015). Grey highlight – BsaI recognition site. Pink highlight – BsmBI recognition 
site. Bold – BsaI/BsmBI generated overhang. Blue highlight – GFP dropout. Green highlight – start codon. Red highlight – 
stop codon. Underlined – open reading frame. Gpa1-Gɑ chimeras were generated by assembling annealed phosphorylated 
oligonucleotides into the Gpa1 C-terminal Truncation Vector (pWS936) using BsmBI Golden Gate assembly. See Table S2 





































































































































































































































































































































































































































































































Table S4. Plasmids Used in this Study. 
Plasmids listed here are organized by figure number and then by their name within the figure. Each row within the description 
corresponds to a particular cassette or multigene cassette, indicating the selection marker. All plasmids are integration 
cassettes integrating at either the URA3 (URA3 marker), LEU2 (LEU2 marker) or HO (HIS3 marker) locus. 
 
Figure Name Description Strain 
2D+2E, Ste2 pCCW12 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Ste2 pHHF2 pFUS1-sfGFP-tTDH1-pHHF2-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Ste2 pHTB2 pFUS1-sfGFP-tTDH1-pHTB2-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Ste2 pPOP6 pFUS1-sfGFP-tTDH1-pPOP6-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Ste2 pPSP2 pFUS1-sfGFP-tTDH1-pPSP2-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Ste2 pREV1 pFUS1-sfGFP-tTDH1-pREV1-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pPSP2 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pPSP2-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pREV1 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pREV1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pPOP6 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pPOP6-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pRNR2 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pRNR2-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pRET2 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pRET2-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pALD6 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pALD6-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pHTB2 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pHTB2-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pPAB1 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pPAB1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pRNR1 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pRNR1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pHHF1 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pHHF1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pHHF2 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pHHF2-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pPGK1 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pRPL18B pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pRPL18B-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pTEF2 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pTEF2-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pTEF1 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pTEF1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pTDH3 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pTDH3-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Gpa1 pCCW12 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pCCW12-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
2D+2E, Ste4-2A-Ste18 pREV1 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pREV1-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
2D+2E, Ste4-2A-Ste18 pPOP6 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pPOP6-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
2D+2E, Ste4-2A-Ste18 pPSP2 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pPSP2-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
2D+2E, Ste4-2A-Ste18 pRET2 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pRET2-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
2D+2E, Ste4-2A-Ste18 pSAC6 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pSAC6-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
2D+2E, Ste4-2A-Ste18 pRNR2 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pRNR2-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
2D+2E, Ste4-2A-Ste18 pPAB1 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pPAB1-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
2D+2E, Ste4-2A-Ste18 pRNR1 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pRNR1-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
2D+2E, Ste4-2A-Ste18 pRPL18B pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pRPL18B-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
2D+2E, Ste4-2A-Ste18 pHTB2 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pHTB2-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
2D+2E, Ste4-2A-Ste18 pALD6 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pALD6-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
2D+2E, Ste4-2A-Ste18 pHHF1 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pHHF1-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
2D+2E, Ste4-2A-Ste18 pHHF2 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pHHF2-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
2D+2E, Ste4-2A-Ste18 pTEF2 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pTEF2-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
2D+2E, Ste4-2A-Ste18 pTEF1 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pTEF1-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
2D+2E, Ste4-2A-Ste18 pTDH3 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pTDH3-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
3D LexO (1x) LexO (1x)-pLEU2m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3D LexO (2x) LexO (2x)-pLEU2m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3D LexO (3x) LexO (3x)-pLEU2m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3D LexO (4x) LexO (4x)-pLEU2m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3D LexO (6x) LexO (6x)-pLEU2m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD2-LexA-PRD-tENO1-URA3 yWS677 
3D LexO (8x) LexO (8x)-pLEU2m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3D pCCW12 pCCW12-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3E pRNR2m LexO (6x)-pRNR2m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3E pCUP1m LexO (6x)-pCUP1m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3E pCYC1m LexO (6x)-pCYC1m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3E pPHO5m LexO (6x)-pPHO5m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3E pGAL1m LexO (6x)-pGAL1m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3E pCCW12m LexO (6x)-pCCW12m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3E pLEU2m LexO (6x)-pLEU2m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3E pPGK1m LexO (6x)-pPGK1m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3E pALD6m LexO (6x)-pALD6m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3E pTDH3m LexO (6x)-pTDH3m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3E pTEF2m LexO (6x)-pTEF2m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3E pRNR1m LexO (6x)-pRNR1m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
3G+3H TetR-PRD TetO (7x)-pLEU2m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-TetR-PRD-tENO1-URA3 yWS677 
3J+3K Z3E-PRD pZ3-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-Z3EV-PRD-tENO1-URA3 yWS677 
4A+4B Quasi-WT pFUS1-sfGFP-tTDH1-URA3 yWS677 
4A+4B Design 1 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pPOP6-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
4A+4B Design 2 pFUS1-sfGFP-tTDH1-pSAC-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
4A+4B Design 3 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
4A+4B Design 4 LexO(6x)-pLEU2m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
4D mam2 – yWS677 LexO (6x)-pLEU2m-sfGFP-tTDH1-pCCW12-Mam2-tSSA1-pPGK1-GPA1-Sp gpa1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
5A (top) High sensitivity LexO (6x)-pLEU2m-sfGFP-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pCCW12-A2BR-tTDH1-LEU2 yWS677 
5A (top) Mid sensitivity LexO (6x)-pLEU2m-sfGFP-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pHHF2-A2BR-tTDH1-LEU2 yWS677 
5A (top) Low sensitivity LexO (6x)-pLEU2m-sfGFP-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pRPL18B-A2BR-tTDH1-LEU2 yWS677 
5A (bottom) High sensitivity LexO (2x)-pPHO5m-sfGFP-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pCCW12-A2BR-tTDH1-LEU2 yWS677 
5A (bottom) Mid sensitivity LexO (3x)-pPHO5m-sfGFP-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pHHF2-A2BR-tTDH1-LEU2 yWS677 
5A (bottom) Low sensitivity LexO (6x)-pLEU2m-sfGFP-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pRPL18B-A2BR-tTDH1-LEU2 yWS677 
5B Single pop. LexO (6x)-pLEU2m-sfGFP-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pHHF2-A2BR-tTDH1-LEU2 yWS677 
5C Mixed pop. 1/3 LexO (2x)-pPHO5m-sfGFP-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pCCW12-A2BR-tTDH1-LEU2 yWS677 
5C Mixed pop. 2/3 LexO (3x)-pPHO5m-sfGFP-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pHHF2-A2BR-tTDH1-LEU2 yWS677 
5C Mixed pop. 2/3 LexO (6x)-pLEU2m-sfGFP-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pRPL18B-A2BR-tTDH1-LEU2 yWS677 
5F Single pop. LexO (6x)-pLEU2m-MF(ALPHA)1-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pHHF2-MTNR1A-tTDH1-LEU2 yWS677 
5G Mixed pop. 1/2 









6A Single pop. LexO (6x)-pLEU2m-MF(ALPHA)1-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pHHF2-MTNR1A-tTDH1-LEU2 yWS677 
6B+6D Mixed pop. 1/2 LexO(2x)-pRNR2m-sfGFP-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pCCW12-MTNR1A-tTDH1-LEU2 yWS677 
6B+6D Mixed pop. 2/2 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-PRD-tENO1-URA3 pALD6-MTNR1A-tTDH1-LEU2 yWS677 
6F-6H Single pop. 




6F-6H Mixed pop. 1/2 









S1G sfGFP pRPL18B-sfGFP-tPGK1-URA3 yWS677 
S1G mRuby2 pHHF1-mRuby2-tENO2-LEU2 yWS677 
S1G mTagBFP2 pTDH3-mTagBFP2-tTDH1-HIS3 yWS677 
S2A BY4741 pFUS1-sfGFP-tTDH1-URA3 yWS677 
S2A Quasi-WT pFUS1-sfGFP-tTDH1-URA3 yWS677 
S2A Quasi-WT + Sst2 pFUS1-sfGFP-tTDH1-URA3 pCCW12-Sst2-tTDH1-LEU2 yWS677 
S2B+S2C pREV1 pREV1-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pPSP2 pPSP2-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pPOP6 pPOP6-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pRAD27 pRAD27-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pRNR2 pRNR2-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pSAC6 pSAC6-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pRET2 pRET2-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pPAB1 pPAB1-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pALD6 pALD6-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pRNR1 pRNR1-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pRPL18B pRPL18B-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pHTB2 pHTB2-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pPGK1 pPGK1-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pHHF1 pHHF1-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pTEF1 pTEF1-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pHHF2 pHHF2-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pTEF2 pTEF2-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pTDH3 pTDH3-sfGFP-tTDH1-URA3 Quasi-WT 
S2B+S2C pCCW12 pCCW12-sfGFP-tTDH1-URA3 Quasi-WT 
S2E+S2F STE2  STE2-GFP 
S2E+S2F GPA1  GPA1-GFP 
S2E+S2F STE12  STE12-GFP 
S2E+S2F pREV1 pREV1-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pPSP2 pPSP2-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pPOP6 pPOP6-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pRAD27 pRAD27-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pRNR2 pRNR2-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pSAC6 pSAC6-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pRET2 pRET2-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pPAB1 pPAB1-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pALD6 pALD6-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pRNR1 pRNR1-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pRPL18B pRPL18B-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pHTB2 pHTB2-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pPGK1 pPGK1-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pHHF1 pHHF1-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pTEF1 pTEF1-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pHHF2 pHHF2-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pTEF2 pTEF2-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pTDH3 pTDH3-sfGFP-tTDH1-URA3 yWS677 
S2E+S2F pCCW12 pCCW12-sfGFP-tTDH1-URA3 yWS677 
S2H pFUS1 reporter pFUS1-sfGFP-tTDH1-URA3 Quasi-WT 
S2H pFIG1 reporter pFIG1-sfGFP-tTDH1-URA3 Quasi-WT 
S3A+S3B pPSP2 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pPSP2-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pREV1 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pREV1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pPOP6 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pPOP6-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pRNR2 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pRNR2-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pRET2 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pRET2-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pALD6 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pALD6-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pHTB2 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pHTB2-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pPAB1 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pPAB1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pRNR1 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pRNR1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pHHF1 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pHHF1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pHHF2 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pHHF2-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pPGK1 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pRPL18B pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pRPL18B-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pTEF2 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pTEF2-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pTEF1 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pTEF1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pTDH3 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pTDH3-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3A+S3B pCCW12 pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pCCW12-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S3C+S3D pREV1 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pREV1-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S3C+S3D pPOP6 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pPOP6-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S3C+S3D pPSP2 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pPSP2-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S3C+S3D pRET2 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pRET2-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S3C+S3D pSAC6 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pSAC6-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S3C+S3D pRNR2 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pRNR2-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S3C+S3D pPAB1 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pPAB1-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S3C+S3D pRNR1 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pRNR1-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S3C+S3D pRPL18B pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pRPL18B-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S3C+S3D pHTB2 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pHTB2-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S3C+S3D pALD6 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pALD6-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S3C+S3D pHHF1 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pHHF1-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S3C+S3D pHHF2 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pHHF2-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S3C+S3D pTEF2 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pTEF2-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S3C+S3D pTEF1 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pTEF1-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S3C+S3D pTDH3 pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2- pTDH3-STE4-2A-STE18-tADH1-pRAD27-STE12-tENO1-pFUS1-sfGFP-tTDH1-URA3 yWS1922 
S4A pTDH3 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pTDH3-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pTEF1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pTEF1-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pTEF2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pTEF2-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pHHF2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pHHF2-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pHTB2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pHTB2-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pHHF1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pHHF1-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pRNR1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRNR1-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pRPL18B pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRPL18B-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pPAB1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pPAB1-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pALD6 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pALD6-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pRET2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRET2-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pSAC6 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pSAC6-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pPOP6 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pPOP6-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pRNR2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRNR2-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pRAD27 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pPSP2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pPSP2-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pREV1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pREV1-STE12-tENO1-URA3 Spacer1-Spacer2-LEU2 yWS677 
S4A pTDH3 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pTDH3-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pTEF1 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pTEF1-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pTEF2 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pTEF2-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pHHF2 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pHHF2-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pHTB2 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pHTB2-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pHHF1 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pHHF1-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pRNR1 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRNR1-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pRPL18B + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRPL18B-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pPAB1 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pPAB1-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pALD6 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pALD6-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pRET2 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRET2-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pSAC6 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pSAC6-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pPOP6 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pPOP6-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pRNR2 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRNR2-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pRAD27 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pPSP2 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pPSP2-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pREV1 + Dig1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pREV1-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-Spacer2-LEU2 yWS677 
S4A pTDH3 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pTDH3-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pTEF1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pTEF1-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pTEF2 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pTEF2-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pHHF2 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pHHF2-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pHTB2 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pHTB2-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pHHF1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pHHF1-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pRNR1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRNR1-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pRPL18B + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRPL18B-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pPAB1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pPAB1-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pALD6 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pALD6-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pRET2 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRET2-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pSAC6 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pSAC6-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pPOP6 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pPOP6-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pRNR2 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRNR2-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pRAD27 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pPSP2 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pPSP2-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pREV1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pREV1-STE12-tENO1-URA3 Spacer1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pTDH3 + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pTDH3-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pTEF1 + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pTEF1-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pTEF2 + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pTEF2-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pHHF2 + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pHHF2-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pHTB2 + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pHTB2-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pHHF1 + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pHHF1-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pRNR1 + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRNR1-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pRPL18B + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRPL18B-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pPAB + Dig1 + Dig21 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pPAB1-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pALD6 + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pALD6-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pRET2 + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRET2-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pSAC6 + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pSAC6-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pPOP6 + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pPOP6-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pRNR2 + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRNR2-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pRAD27 + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pPSP2 + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pPSP2-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4A pREV1 + Dig1 + Dig2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pREV1-STE12-tENO1-URA3 pCCW12-DIG1-tADH1-pTDH3-DIG2-tTDH1-LEU2 yWS677 
S4C Quasi-WT pFUS1-sfGFP-tTDH1-URA3 Quasi-WT 
S4C Design 4 LexO(6x)-pLEU2m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 yWS677 
S4E pSTE2-sfGFP-tSTE2 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 STE2-GFP 
S4E pGPA1-sfGFP-tGPA1 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 GPA1-GFP 
S4E pSTE12-sfGFP-tSTE12 pFUS1-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 STE12-GFP 
S4G Quasi-WT pFUS1-sfGFP-tTDH1-URA3 Quasi-WT 
S4G Design 1 – w/o feedback pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pPOP6-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 yWS677 
S4G Design 2 – w/ feedback pFUS1-sfGFP-tTDH1-pSAC6-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-STE12-tENO1-URA3 pFUS1-STE2-tTDH1-pFUS1-GPA1-tADH1-pFUS1-STE12-tENO1-LEU2 yWS677 















S4I BY4741  BY4741 
S4I yWS677  yWS677 
S4I yWS1922  yWS1922 
S4J Quasi-WT pFUS1-sfGFP-tTDH1-URA3 Quasi-WT 















S6A GPA1 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-A2BR-tSSA1-LEU2 yWS677 
S6A GPA1-Gɑs LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑs-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-A2BR-tSSA1-LEU2 yWS677 
S6A GPA1-Gɑ12 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑ12-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-A2BR-tSSA1-LEU2 yWS677 
S6A GPA1-Gɑi1/2 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑi1/2-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-A2BR-tSSA1-LEU2 yWS677 
S6A GPA1-Gɑi3 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑi3-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-A2BR-tSSA1-LEU2 yWS677 
S6A GPA1-Gɑz LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑz-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-A2BR-tSSA1-LEU2 yWS677 
S6A GPA1-Gɑ15/16 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑ15/16-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-A2BR-tSSA1-LEU2 yWS677 
S6A GPA1-Gɑq/11 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑq/11-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-A2BR-tSSA1-LEU2 yWS677 
S6A GPA1-Gɑ14 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑ14-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-A2BR-tSSA1-LEU2 yWS677 
S6A GPA1-Gɑo LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑo-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-A2BR-tSSA1-LEU2 yWS677 
S6A tGPA1 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-tGPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-A2BR-tSSA1-LEU2 yWS677 
S6B GPA1 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-MTNR1A-tSSA1-LEU2 yWS677 
S6B GPA1-Gɑs LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑs-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-MTNR1A-tSSA1-LEU2 yWS677 
S6B GPA1-Gɑ12 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑ12-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-MTNR1A-tSSA1-LEU2 yWS677 
S6B GPA1-Gɑi1/2 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑi1/2-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-MTNR1A-tSSA1-LEU2 yWS677 
S6B GPA1-Gɑi3 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑi3-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-MTNR1A-tSSA1-LEU2 yWS677 
S6B GPA1-Gɑz LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑz-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-MTNR1A-tSSA1-LEU2 yWS677 
S6B GPA1-Gɑ15/16 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑ15/16-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-MTNR1A-tSSA1-LEU2 yWS677 
S6B GPA1-Gɑq/11 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑq/11-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-MTNR1A-tSSA1-LEU2 yWS677 
S6B GPA1-Gɑ14 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑ14-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-MTNR1A-tSSA1-LEU2 yWS677 
S6B GPA1-Gɑo LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-Gɑo-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-MTNR1A-tSSA1-LEU2 yWS677 
S6B tGPA1 LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-tGPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-MTNR1A-tSSA1-LEU2 yWS677 
S6C A2BR LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pHHF2-A2BR-tSSA1-LEU2 yWS677 
S6D MTNR1A LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pHHF2-MTNR1A-tSSA1-LEU2 yWS677 













































S7A+S7B High sensitivity LexO (6x)-pLEU2m-sfGFP-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pCCW12-A2BR-tTDH1-LEU2 yWS677 
S7A+S7B Mid sensitivity LexO (6x)-pLEU2m-sfGFP-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pHHF2-A2BR-tTDH1-LEU2 yWS677 
S7A+S7B Low sensitivity LexO (6x)-pLEU2m-sfGFP-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pRPL18B-A2BR-tTDH1-LEU2 yWS677 
S7D+S7E Cell 1 LexO (6x)-pLEU2m-MF(ALPHA)1-tTDH1-Spacer 2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pHHF2-MTNR1A-tTDH1-LEU2 yWS677 
S7D+S7E Cell 2: No Bar1 LexO(6x)-pCUP1m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 Spacer-HIS3 yWS677 
S7D+S7E Cell 2: pRPL18B LexO(6x)-pCUP1m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pRPL18B-BAR1-tTDH1-HIS3 yWS677 
S7D+S7E Cell 2: pPGK1 LexO(6x)-pCUP1m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pPGK1-BAR1-tTDH1-HIS3 yWS677 
S7D+S7E Cell 2: pTDH3 LexO(6x)-pCUP1m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pTDH3-BAR1-tTDH1-HIS3 yWS677 
S7D+S7E Cell 2: pCCW12 LexO(6x)-pCUP1m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pCCW12-BAR1-tTDH1-HIS3 yWS677 
S7F Single pop. LexO(6x)-pLEU2m-sfGFP-tTDH1-Spacer2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pHHF2-MTNR1A-tTDH1-LEU2 yWS677 
S7G Mixed pop. 1/2 LexO(6x)-pLEU2m-MF(ALPHA)1-tTDH1-Spacer2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pHHF2-MTNR1A-tTDH1-LEU2 yWS677 
S7G Mixed pop. 2/2 LexO(6x)-pCUP1m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pRPL18B-BAR1-tTDH1-HIS3 yWS677 
S7H Mixed pop. 1/2 LexO(6x)-pLEU2m-MF(ALPHA)1-tTDH1-Spacer2-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pALD6-MTNR1A-tTDH1-LEU2 yWS677 
S7H Mixed pop. 2/2 LexO(6x)-pCUP1m-sfGFP-tTDH1-pCCW12-STE2-tSSA1-pPGK1-GPA1-tENO2-pRAD27-LexA-PRD-tENO1-URA3 pRPL18B-BAR1-tTDH1-HIS3 yWS677 
 
